Pyrimidine compound and pharmaceutical composition comprising the same for preventing or treating cancer
By developing novel pyrimidine compounds, the problem of insufficient kinase inhibitors in existing technologies has been solved, achieving highly efficient inhibition of FLT3, VEGFR, and SYK, and significantly improving the efficacy of cancer treatment.
Patent Information
- Application Number
- CN202310204523.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-25
- Filing Date
- 2019-02-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-02-13
AI Technical Summary
Current technologies lack effective kinase inhibitors, especially inhibitors targeting kinases such as FLT3, VEGFR, and SYK, leading to poor treatment outcomes for cancers such as leukemia.
A novel pyrimidine compound was developed that inhibits the activity of these kinases by binding to specific sites, thereby controlling cell signaling and cell proliferation.
This compound exhibits highly potent inhibitory activity against FLT3, VEGFR, and SYK, significantly improving the treatment outcomes for cancers such as AML, and is particularly effective against other diseases.
Smart Images

Figure BDA0004110305710000051 
Figure BDA0004110305710000061 
Figure BDA0004110305710000062
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201980049569.8 (application date: February 13, 2019, invention name: pyrimidine compounds and pharmaceutical compositions comprising the same for preventing or treating cancer). Technical Field
[0002] The present invention relates to a novel pyrimidine compound, a preparation method thereof and a pharmaceutical use thereof. Background Art
[0003] Kinases mediate a reaction in which a phosphate group from a high energy molecule, particularly ATP, is transferred to a substrate. Kinases stabilize the phosphoanhydride bond and position the substrate and the phosphate group at a specific position to increase the reaction rate. In most cases, the transition state generated by the interaction with the negatively charged phosphate group is electrostatically stabilized by surrounding amino acids with positive charges, and some kinases can coordinate with the phosphate group through metal cofactors.
[0004] According to substrate and characteristics, kinase can be classified into, for example, protein kinase, lipid kinase and carbohydrate kinase. Protein, lipid or carbohydrate can be different in its activity, reactivity, ability to combine with other molecules, etc., depending on phosphorylation state. Kinase affects intracellular signal transmission and regulates complex biological mechanisms in cells. Due to phosphorylation, some molecules can have enhanced or reduced activity, and can control their ability to interact with other molecules. Because many kinases respond to environmental conditions or signals, cells can depend on the specific circumstances and control intracellular molecules by using kinase. Therefore, kinase plays a key role in cell growth, differentiation, proliferation, survival, metabolism, signal transmission, cell transport, secretion and many other cell response pathways.
[0005] Kinases have been found in a variety of species including bacteria, fungi, insects, and mammals, and to date 500 or more kinases have been discovered in humans.
[0006] Protein kinases can increase or decrease the activity of proteins, become markers for stability or degradation, place proteins in specific cell compartments, or initiate or interfere with the interaction of proteins with other proteins. Known protein kinases account for the majority of kinases and are considered to be important research targets. Protein kinases regulate protein and enzyme and cell signaling together with phosphatases. Although cellular proteins are subjected to numerous covalent bonds, not many of these bonds are reversible. Therefore, it can be said that the phosphorylation of proteins has a regulatory function. Protein kinases can often have a variety of substrates, and sometimes specific proteins can serve as substrates for at least one kinase. For this reason, protein kinases are named using factors that regulate their activity. For example, calmodulin-dependent protein kinases are regulated by calmodulin. In some cases, kinases can be classified into subgroups. For example, type I and type II cyclic AMP-dependent protein kinases include consistent enzyme subunits, but their regulatory subunits that are combined with cyclic AMP are different from each other.
[0007] Protein kinases are enzymes that catalyze the phosphorylation of hydroxyl groups located in tyrosine, serine and threonine residues of proteins and play an important role in signaling growth factors that induce cell growth, differentiation and proliferation (Melnikova, I. et al. Nature Reviews Drug Discovery, 3 (2004), 993), and it has been reported that abnormal expression or mutation of specific kinases often occurs in cancer cells.
[0008] As one of the ways of cell recognition external stimulation, identification via tyrosine kinase (receptor in cell membrane) can be used. Receptor tyrosine kinase (RTK) is composed of the extracellular part exposed to the outside of the cell, the intracellular part exposed to the intracellular cytoplasm and the transmembrane part of the protoplasm membrane between the extracellular part and the intracellular part. The cell outside of the receptor is divided into the part bound by a specific ligand, and the intracellular part acts to transmit the activation signal of the receptor activated by the ligand into the cell. RTK has a domain with tyrosine kinase activity in the C-terminal region exposed to the cell, and when a specific ligand is attached to the extracellular part, the kinase enzyme of the C-terminal tyrosine kinase domain of the receptor protein exposed to the cytoplasmic part is activated, and the two RTK cross-phosphorylates the tyrosine of the C-terminal of the adjacent RTK. The phosphorylation process of this tyrosine is the most important process in the signal transmission corresponding to the extracellular stimulation entering the cell. There are many known receptors with tyrosine kinase activity, which are used to transmit extracellular stimulation into the cell based on this mechanism. Examples of such receptors are FLT3, VEGFR and SYK.
[0009] Among these, FMS-like tyrosine kinase 3 (FLT3) as receptor tyrosine kinase is normally expressed by hematopoietic progenitor cells, and plays an important role in the expression of normal stem cells and the immune system. The abnormal overexpression and mutation of FLT3 are often found in leukemia patients. Especially, various mutations of FLT3 such as D835V, D835Y and internal tandem duplication (ITD) are found in acute myeloid leukemia (AML). AML is a hematopoietic stem cell disorder, characterized in that the abnormal proliferation and differentiation of the mother cells in the bone marrow and peripheral blood. FLT3 is recently regarded as one of the most important targets in the treatment of AML.
[0010] It is reported that RAS and p53 gene mutations in adult AML are approximately 20% and 5% of adult AML, respectively, while FLT3 gene mutations are found in approximately 30% of adult AML. The most typical problem of AML is that FLT3 mutations that cause poor prognosis are activated. FLT3 mutations are divided into two types: one is internal tandem duplication (ITD) in the juxtamembrane domain, and the other is point mutations in the tyrosine kinase domain (TKD). About 23% of early AML patients experience activation of FLT3-ITD, which is the most common mutation. Patients with ITD mutations show poor prognosis and high relapse rates. Another major FLT3 mutation is the FLT3 TKD mutation, which accounts for approximately 7% of initial AML cases. Point mutations in aspartic acid 835 (D835) residues are replaced by various amino acids and are one of the most common mutations, although they occur less frequently than ITD mutations. In addition, another major activation method of FLT3 in AML is overexpression of wild-type FLT3 protein.
[0011] The activation of ITD mutation in FLT3 occurs in about 20% of acute myeloid leukemia patients, which is associated with poor prognosis. Studies have shown that FLT3-ITD is a driving lesion that causes the pathogenesis of malignant tumors, and can be an effective therapeutic target in human AML (non-patent document 1). Mutations in the FLT3 gene often occur in AML, and are usually accompanied by ITD mutations in the near-membrane domain coding region or point mutations in the tyrosine kinase domain (TKD). FLT3-ITD mutations and FLT3-TKD mutations cause ligand-independent proliferation due to the dimerization of components and the activation of FLT3 receptors. FLT3-ITD is associated with poor prognosis in adults and children relative to the high mutation rate of wild-type alleles (non-patent document 2). Other types of leukemia, such as chronic myelomonocytic leukemia (CMML), may also have activation mutations of FLT3. Therefore, FLT3 with activation mutations is an important target for multiple cancer types (non-patent document 3 and non-patent document 4).
[0012] Vascular endothelial growth factor receptor (VEGFR) is a kinase known to be involved in the regulation of angiogenesis. Solid tumors require more nutrition and oxygen than normal tissues. Therefore, compared to the normal state, insufficient blood supply occurs, and the overexpression or activation of VEGFR induces angiogenesis, which is related to the angiogenesis required for tumor cell growth and proliferation (non-patent document 5). Therefore, various clinical studies have been performed to treat tumors by inhibiting angiogenesis, and multiple desired results have been obtained. In addition, VEGF plays an important role in blood cancer and is overexpressed in various malignant solid tumors. Overexpression of VEGF is known to have a high correlation with the disease progression of malignant tumors. VEGFR includes VEGFR-1, VEGFR-2 and VEGFR-3 according to subtype classification. VEGFR-2 (KDR) is a typical target for tumor diseases with VEGFR expression. Representative diseases caused by VEGFR-2 overexpression are lung cancer, breast cancer, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, etc. VEGF is a ligand of VEGFR, which may have angiogenic activity and promote tumor growth through a direct pro-survival effect on tumor cells (non-patent document).
[0013] Spleen tyrosine kinase (SYK) is mainly expressed in hemocytes, and plays an important role in the signal transduction pathways of other immune receptors (such as B cell receptors and mast cells).SYK is expressed in non-hematopoietic cells such as nerve cells and vascular endothelial cells. Recent studies show that SYK acts on the oxidation stimulated by various cells, including IL-1, TNF-α and ITGB1.SYK is known as a good potential target (non-patent document 7 and non-patent document 8) of various hematological malignancies, autoimmune diseases and other inflammatory reactions.
[0014] [Prior art documents]
[0015] (Non-patent document 1) Catherine et al. Nature, 2012, 485: 260-263
[0016] (Non-patent document 2) AS Moore et al. Leukemia, 2012, 26: 1462-1470
[0017] (Non-patent document 3) Cancer Cell, (2007), 12: 367-380
[0018] (Non-patent document 4) Current Pharmaceutical Design (2005), 11: 3449-3457
[0019] (Non-patent document 5) Kliche, S. et al. J., Life, 52, (2001), 61
[0020] (Non-patent document 6) Simons, M. et al. Nature Reviews molecular cell biology, 17, (2016), 611
[0021] (Non-patent document 7) Liu et al. Journal of Hematology & Oncology (2017) 10: 145
[0022] (Non-patent document 8) Yamada T et al. J. Immunol., (2001) 167, 283-288 Summary of the invention
[0023] Technical issues
[0024] Provided are novel pyrimidine compounds having kinase inhibitory activity.
[0025] A method for preparing the pyrimidine compound is provided.
[0026] The invention provides pharmaceutical use of the pyrimidine compound.
[0027] Technical Solution
[0028] Additional aspects will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the presented embodiments.
[0029] According to one aspect of one embodiment, provided is a compound selected from the compounds represented by Formula 1, and a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof:
[0030] [Formula 1]
[0031]
[0032] Among them, in formula 1,
[0033] R 1 It can be hydrogen, halogen, hydroxyl, C1-C4 alkoxy or -NR a R b ,
[0034] Where R a and R b may each independently be hydrogen or C1-C4 alkyl;
[0035] R 2 It can be hydrogen, halogen, cyano, nitro, amino, carboxamide, formyl, halogenated C1-C4 alkyl or C1-C4 alkyl;
[0036] R 3It can be hydrogen, halogen, hydroxyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl;
[0037] R 4 can be independently hydrogen, halogen, hydroxyl, cyano, nitro, amino, S(=O) l -R c , halogenated C 1- C4 alkyl, C 1- C4 alkoxy, hydroxyl 1- C4 alkyl, C 1- C4 alkyl, C 2- C4 alkenyl, C 2- C4 alkynyl, -NR d R e 、-CO2R e , or -CO-NR d R e ,
[0038] Where R c is C1-C4 alkyl or -NR d R e ,
[0039] R d and R e are each independently hydrogen or C1-C4 alkyl, and
[0040] I can be an integer from 0 to 2;
[0041] k can be an integer from 0 to 4;
[0042] R 5 and R 6 can be each independently hydrogen, halogen, hydroxy, nitro, amino, C1-C4 alkoxy or C1-C4 alkyl;
[0043] R 7 It can be hydroxyl C 1- C4 alkyl, C 1- C4 alkyl, C 2- C4 alkenyl, C 2- C4 alkynyl, C 3- C7 cycloalkyl or C 3- C9 heterocycloalkyl,
[0044] Wherein C 3- C7 cycloalkyl or the C 3- The C9 heterocycloalkyl group may be unsubstituted or substituted with halogen, C 1- C4 alkyl or halogenated C 1- C4 alkyl substituted; and
[0045] X is H or OH;
[0046] Wherein, when X is OH, the compound represented by Formula 1 may include a tautomeric structure represented by Formula 2,
[0047] [Formula 2]
[0048]
[0049] R in Formula 2 3 , R 4 and k may be the same as described with respect to Formula 1;
[0050] Y is -(CH2) m -、-(CH2) m -O-(CH2) n -、-(CH2) m -CO-(CH2) n -、-(CH2) m -NR 8 -(CH2) n -or-(CH2) m -SO2-(CH2) n -,
[0051] Where R 8 is hydrogen or C1-C4 alkyl,
[0052] m and n are each independently an integer from 0 to 2; and
[0053] Z is represented by formula 3;
[0054] [Formula 3]
[0055]
[0056] Among them, in formula 3,
[0057] C3-C 10 Cycloalkyl or C2-C 11 Heterocycloalkyl;
[0058] R 9 is halogen, hydroxyl, cyano, nitro, amino, thiol, formyl, halogenated C 1- C4 alkyl, C 1- C4 alkoxy, straight chain or branched hydroxyl C 1- C4 alkyl, straight chain or branched 1- C4 alkyl, C 2- C4 alkenyl, C 2- C4 alkynyl, C 3- C 10 Cycloalkyl, C 2-C9 heterocycloalkyl, hydroxyl C 2- C9 heterocycloalkyl, straight chain or branched hydroxyl C 1- C4 alkylcarbonyl, -NR 10 R 11 、-COR 12 、-COOR 12 or-SO2R 13 ,
[0059] q can be an integer from 0 to 5,
[0060] Among them, when When is piperazine or piperidine, q is not 0, and
[0061] Two or more R 9 Can be connected or fused to form a 7- to 12-membered bicycloalkyl, heterobicycloalkyl, spirocycloalkyl or spiroheterocycloalkyl;
[0062] R 10 and R 11 may be each independently hydrogen, hydroxy C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl;
[0063] R 12 is hydrogen, hydroxy, hydroxy C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl or C2-C9 heterocycloalkyl;
[0064] R 13 It can be hydroxyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl, C2-C9 heterocycloalkyl, aryl or -NR f R g ,and
[0065] R f and R g They may each independently be hydrogen or C1-C4 alkyl.
[0066] According to an aspect of another embodiment, a method for preparing the compound is provided.
[0067] According to an aspect of another embodiment, a pharmaceutical composition for preventing or treating cancer includes the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
[0068] According to one aspect of another embodiment, a pharmaceutical composition for preventing or treating a FLT3-mediated disease comprises the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
[0069] According to one aspect of another embodiment, a pharmaceutical composition for inhibiting FLT3 kinase activity comprises the compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0070] According to an aspect of another embodiment, a method of reducing FLT3 activity in a subject in need thereof by using the compound is provided.
[0071] According to an aspect of another embodiment, provided is a method for treating a FLT3-mediated disease by using the compound.
[0072] Beneficial Effects
[0073] The compound according to one aspect of the present disclosure is excellent in FLT3 inhibitory activity, and thus is effectively used for preventing or treating cell proliferative diseases caused by abnormal FLT3 activity, such as cancer (eg, leukemia). DETAILED DESCRIPTION
[0074] This disclosure will be described in further detail.
[0075] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although exemplary methods or materials are listed herein, other similar or equivalent methods or materials are also within the scope of the present disclosure. In addition, unless explicitly stated, the numerical values described herein are considered to include the meaning of "about". All publications disclosed herein as references are incorporated by reference in their entirety.
[0076] One aspect of the present disclosure provides a compound selected from the compounds represented by Formula 1, and a stereoisomer, a tautomer, a solvate or a pharmaceutically acceptable salt thereof.
[0077] By R 1 To R 17 ,X,Y,Z,Z',A,B,Q,L or E a To E d The represented residues can be understood in the same manner as those of ordinary skill in the art.
[0078] Unless otherwise specified, the term "halogen" includes fluorine, chlorine, bromine or iodine, and may be, for example, fluorine or chlorine, but is not limited thereto.
[0079] The term "alkyl" refers to a saturated monovalent hydrocarbon group. The term "alkenyl" as used herein refers to a monovalent hydrocarbon group containing at least one carbon-carbon double bond, wherein each double bond may have an E- or Z-stereoconfiguration. The term "alkynyl" as used herein refers to a monovalent hydrocarbon group containing at least one carbon-carbon triple bond. Such alkyl, alkenyl and alkynyl groups may be linear, i.e., straight chain or side chain. As defined above, the number of carbon atoms in the alkyl group may be 1, 2, 3, 4, 5 or 6; or 1, 2, 3 or 4. Examples of alkyl groups include methyl, ethyl, propyl (including n-propyl and isopropyl), n-butyl, sec-butyl, butyl (including isobutyl and tert-butyl), pentyl (including n-pentyl, 1-methylbutyl, isopentyl, neopentyl and tert-pentyl), hexyl (including n-hexyl, 3,3-dimethylbutyl and isohexyl). The double bond of the alkenyl group and the triple bond of the alkynyl group may each be in any position. Examples of alkenyl and alkynyl are vinyl, prop-1-enyl, prop-2-enyl (=allyl), but-2-enyl, 2-methylprop-2-enyl, 3-methylbut-2-enyl, hex-3-enyl, hex-4-enyl, prop-2-enyl (=propargyl), but-2-enyl, but-3-enyl, hex-4-enyl and hex-5-enyl. Substituted alkyl, substituted alkenyl and substituted alkynyl may be substituted at any position in the case where the compounds are each sufficiently stable and suitable for the desired use, e.g., pharmaceutical substances.
[0080] Unless otherwise stated, the term "cycloalkyl" refers to substituted or unsubstituted cycloalkyl, and examples of monocyclic or polycyclic groups are monocyclic or bicyclic aliphatic groups. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantane-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-1-yl, or any suitable isomer thereof, but are not limited thereto.
[0081] Unless otherwise stated, the term "bicycloalkyl" as used herein refers to a saturated carbocyclic ring including two rings, and includes fused carbocyclic rings in which the two rings share two adjacent atoms as part of the ring, and includes bridged carbocyclic rings in which the two rings share two non-adjacent atoms as part of the ring. For example, a 7- to 12-membered bicycloalkyl refers to a fused carbocyclic ring or a bridged carbocyclic ring, each having two rings consisting of a total of 7 to 12 atoms.
[0082] Unless otherwise indicated, the term "heterocycloalkyl" as used herein refers to a substituted or unsubstituted monocyclic or polycyclic alkyl group containing at least one, for example, 1 to 4 heteroatoms selected from O, N and S. Examples of monoheterocyclylalkyl groups are piperazinyl, piperidinyl, piperazinyl-1-oxide, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, diazabicycloheptane, diazabicyclooctane and diazaspirooctane, and groups similar thereto, but are not limited thereto.
[0083] Unless otherwise stated, the term "heterobicycloalkyl" as used herein refers to a bicycloalkyl containing one or more heteroatoms selected from O, N and S, and includes fused heterobicycloalkyl and bridged heterobicycloalkyl. The term "bridging" as used herein refers to a monovalent bond, a single atom or a non-branched atom connecting two different parts within a molecule. In addition, a pair of tertiary or more carbon atoms linked by a bridge is referred to as a "bridgehead". In other words, a carbon atom that participates as part of two or more rings at the same time is called a bridgehead, and the bond connected to these bridgeheads is called a bridge. The term "bridged compound" as used herein refers to a compound in which two or more rings share one or more pairs of carbon atoms.
[0084] Examples of fused heterobicycloalkyl groups include, but are not limited to, indole, quinoline, thiazolo[4,5-b]-pyridine and quinoline, etc. Examples of bridged heterobicycloalkyl groups include, but are not limited to, 7- to 12-membered heterobicycloalkyl groups such as diazabicyclo[2.2.1]heptane or diazabicyclo[3.2.1]octane.
[0085] Unless otherwise defined, the term "spiro" as used herein refers to two rings sharing one atom, wherein the two rings are not connected to each other by a bridge. Unless otherwise defined, the term "spirocycloalkyl" as used herein refers to a saturated carbocyclic ring consisting of two rings, which only shares one carbon atom as a part of the ring. Examples of spirocycloalkyl include 7 to 12 yuan of spirocycloalkyl, such as diazaspiro [2.5] octane, but are not limited thereto. Unless otherwise defined, the term "heterospirocycloalkyl" refers to a spirocycloalkyl containing at least one heteroatom selected from O, N and S. Unless otherwise defined, the expression "spiro connection" as used herein refers to a joint sharing one atom.
[0086] Unless otherwise indicated, the term "aryl" as used herein refers to an aromatic group which may be substituted or unsubstituted, such as phenyl, biphenyl, naphthyl, tolyl, naphthalenyl, anthracenyl, or any suitable isomer thereof, without limitation.
[0087] Unless otherwise stated, the term "heteroaryl" as used herein refers to a monocyclic or bicyclic or higher aromatic group containing at least one heteroatom selected from O, N and S, for example 1 to 4 heteroatoms. Examples of monocyclic heteroaryl groups are thiazolyl, oxazolyl, phenylthio, furanyl, pyrrolyl, imidazolyl, isoxazolyl, pyrazolyl, triazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, but examples are not limited thereto. Examples of bicyclic heteroaryl groups are indolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, quinolyl, isoquinolyl, purinyl and furopyridinyl, but examples are not limited thereto.
[0088] Unless otherwise defined, the term "alkylene bridge" refers to a straight or branched divalent hydrocarbon bridge connecting two different carbons having the same ring structure, which may be composed of carbon and hydrogen, is non-unsaturated, and may have, for example, 3 to 6 carbon atoms, and examples thereof are propylene and n-butene, etc. The alkylene bridge may link any two carbons in the ring structure. At least one methylene group in the alkylene bridge may be substituted by at least one selected from -O-, -S-, -S(O)-, -S(O)2-, and -N(R')-, wherein R' may be hydrogen, C 1- C6 alkyl, C 3- C7 cycloalkyl or aryl. In the present specification, a numerical range expressed using the term "to" means including the numerical range described before and after the term as the lower limit and the upper limit, respectively.
[0089] In an exemplary embodiment of one aspect of the present disclosure, R 1 It may be hydrogen, C1-C4 alkoxy or hydroxy.
[0090] In one embodiment, R in the compound of Formula 1 1 It may be hydrogen, halogen, hydroxy or C1-C4 alkoxy.
[0091] In one embodiment, R in the compound of Formula 1 2 It can be hydrogen, halogen, C 1- C4 alkyl or halogenated C 1-4 alkyl.
[0092] In one embodiment, R in the compound of Formula 1 3 It can be hydrogen, hydroxyl, or C1-C4 alkyl. In one embodiment, R 3 It may be hydrogen.
[0093] In one embodiment, R in the compound of Formula 1 4 It can be hydrogen, halogen, hydroxyl, cyano, nitro, amino, halogenated C 1-4In one embodiment, R 4 It may be hydrogen, halogen, hydroxy, C1-C4 alkoxy, hydroxyC1-C4 alkyl or C1-C4 alkyl.
[0094] In one embodiment, R in the compound of Formula 1 5 and R 6 can be independently hydrogen, halogen, hydroxyl, cyano or C1-C4 alkyl. 5 and R 6 Each may independently be hydrogen or hydroxy.
[0095] In one embodiment, R in the compound of Formula 1 7 It can be a C3-C7 cycloalkyl group. In one embodiment, R 7 It may be cyclopropyl.
[0096] In one embodiment, Y in the compound of formula 1 may be -(CH2) m -、-(CH2) m -O-(CH2) n -or-(CH2) m -CO-(CH2) n -, wherein m and n can each independently be an integer from 0 to 2. In one embodiment, Y can be -(CH2) m -, wherein m can be an integer selected from 1 and 2.
[0097] In one embodiment, Z in the compound of Formula 1 may be a compound represented by Formula 3.
[0098] Formula 3
[0099]
[0100] Among them, in formula 3,
[0101] Can be C3-C 10 Cycloalkyl or C2-C 11 Heterocycloalkyl;
[0102] R 9 It can be halogen, hydroxyl, cyano, nitro, amino, thiol, formyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, straight-chain or branched hydroxy C1-C4 alkyl, straight-chain or branched C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl, C2-C9 heterocycloalkyl, hydroxy C2-C9 heterocycloalkyl, straight chain or branched hydroxy C1-4 Alkylcarbonyl, -NR 10 R 11 、-COR 12 、-COOR 12 or-SO2R 13 ,
[0103] q can be an integer from 0 to 5 independently.
[0104] Among them, when When is piperazine or piperidine, q may not be 0, and
[0105] Two or more R 9 Can be connected to each other or with fused to form a 7- to 12-membered bicycloalkyl;
[0106] R 10 and R 11 can be independently hydrogen, hydroxyl C 1- C4 alkyl, halogenated C 1- C4 alkyl, C 1- C4 alkyl, C 2- C4 alkenyl or C 2- C4 alkynyl;
[0107] R 12 Hydrogen, hydroxyl, hydroxyl C 1- C4 alkyl, halogenated C 1- C4 alkyl, C 1- C4 alkyl, C 2- C4 alkenyl, C 2- C4 alkynyl, C 3- C 10 Cycloalkyl or C 2- C9 heterocycloalkyl;
[0108] R 13 Hydroxyl, halogenated C 1- C4 alkyl, C 1- C4 alkyl, C 2- C4 alkenyl, C 2- C4 alkynyl, C 3- C 10 Cycloalkyl, C 2- C9 heterocycloalkyl, aryl or -NR f R g ,and
[0109] R f and R g are independently hydrogen or C 1- C4 alkyl.
[0110] In the example of Formula 3,
[0111] It may be a C3-C6 heterocycloalkyl group including one or two heteroatoms selected from O, N and S;
[0112] R 9 can be independently hydrogen, hydroxyl, straight chain or branched chain hydroxyl C 1- C4 alkyl, straight chain or branched 1- C4 alkyl, C 3- C 10 Cycloalkyl, C 2- C9 heterocycloalkyl, hydroxyl C 2- C9 heterocycloalkyl, -NR 10 R 11 or-COR 12 ,
[0113] R 10 and R 11 can be independently hydrogen, hydroxyl C 1- C4 alkyl or C 1- C4 alkyl; and
[0114] R 12 Can be hydrogen, hydroxyl, hydroxyl C 1- C4 alkyl, halogenated C 1- C4 alkyl or C 1- C4 alkyl.
[0115] In an exemplary embodiment, in the compound of Formula 1,
[0116] X is H or OH,
[0117] Wherein, when X is OH, the compound represented by Formula 1 may include a tautomeric structure represented by Formula 2:
[0118] [Formula 2]
[0119]
[0120] R in Formula 2 3 , R 4 and k are the same as described with respect to Formula 1.
[0121] In an exemplary embodiment, in the compound of Formula 1,
[0122] X is H or OH,
[0123] Wherein, when X is OH, the compound represented by Formula 1 may include a tautomeric structure represented by Formula 2:
[0124] R 1 It can be hydrogen, hydroxyl, C 1- C4 alkoxy or C 1-C4 alkyl;
[0125] R 2 It can be hydrogen, halogen, C 1- C4 alkyl or halogenated C 1- C4 alkyl;
[0126] R 3 It can be hydrogen;
[0127] R 4 It can be hydrogen, halogen, hydroxyl, C 1- C4 alkoxy, hydroxyl 1- C4 alkyl or C 1- C4 alkyl;
[0128] k can be an integer from 0 to 2;
[0129] R 5 and R 6 may each independently be hydrogen or hydroxyl;
[0130] R 7 It may be cyclopropyl;
[0131] Y can be -(CH2) m -、-(CH2) m -O-(CH2) n -or-(CH2) m -CO-(CH2) n -;
[0132] m and n are each independently an integer from 0 to 2; and
[0133] Z can be Formula 3;
[0134] [Formula 3]
[0135]
[0136] Among them, in formula 3,
[0137] It may be a C3-C6 heterocycloalkyl group including one or two heteroatoms selected from O, N and S;
[0138] R 9 can be independently hydroxyl, hydroxyl C 1- C4 alkyl, C 1- C4 alkyl, C 3- C 10 Cycloalkyl, C 2- C9 heterocycloalkyl, hydroxyl C 2- C9 heterocycloalkyl, -NR 10 R 11 or-COR12 ,
[0139] R 10 and R 11 can be independently hydrogen, hydroxyl C 1- C4 alkyl or C 1- C4 alkyl;
[0140] R 12 Can be hydrogen, hydroxyl C 1- C4 alkyl, halogenated C 1- C4 alkyl or C 1- C4 alkyl, and
[0141] q may be an integer from 0 to 3 for each independent number.
[0142] In the example of the compound represented by Formula 1, when When it is piperazine or piperidine, q may not be 0.
[0143] In the example of the compound represented by Formula 1, Z may be any one selected from Formula 11 to Formula 13.
[0144] [Formula 11]
[0145]
[0146] [Formula 12]
[0147]
[0148] [Formula 13]
[0149]
[0150] Wherein, in Formulas 11 to 13,
[0151] V and W may each independently be N or CH, provided that V and W are not each CH at the same time,
[0152] R 14 It can be hydrogen, halogen, straight chain or branched C 1- C4 alkyl, linear or branched hydroxyl C 1- C4 alkyl, hydroxyl, -NR 16 R 17 , straight chain or branched hydroxy C1-C4 alkylcarbonyl, C2-C9 heterocycloalkyl, hydroxy C2-C9 heterocycloalkyl, straight chain or branched halogenated C 1- C4 alkyl and straight or branched C 1- C4 alkoxy,
[0153] R 15 Each independently may be a straight chain or a branched chain C 1-C4 alkyl, linear or branched hydroxyl C 1- C4 alkyl or halogen,
[0154] R 14 and R 15 can be connected to each other, or R 14 or R 15 is fused with a cyclic compound represented by one of Formulae 11 to 13 to form a 7- to 12-membered bicycloalkyl, heterobicycloalkyl, spirocycloalkyl or spiroheterocycloalkyl,
[0155] R 16 and R 17 can be independently hydrogen, straight chain or branched C 1- C4 alkyl, or straight chain or branched hydroxyl C 1- C4 alkyl,
[0156] p can be an integer from 0 to 4, and
[0157] When R 14 When R is hydrogen, s and t may each independently be an integer from 0 to 5, and when R 14 When it is not hydrogen, it is an integer from 0 to 4.
[0158] By adding R 14 and R 15 Connect to each other, or R 14 or R 15 Examples of the 7- to 12-membered bicycloalkyl group formed by condensing with the cyclic compound represented by any one of Formulas 11 to 13 are diazabicycloheptyl and diazabicyclooctyl. In one embodiment, the 7- to 12-membered bicycloalkyl group may be 2,5-diazabicyclo[2.2.1]heptyl or 3,8-diazabicyclo[3.2.1]octyl. 14 and R 15 Connect to each other, or R 14 or R 15 Examples of the 7- to 12-membered spirocycloalkyl group formed by condensation with the cyclic compound represented by any one of Formulae 11 to 13 may include an azaspiroctane group, such as a diazaspiro[2.5]octane group.
[0159] In the example of the compound represented by Formula 1, R 7 Can be C 3- C7 cycloalkyl, and Z can be substituted or unsubstituted C 2- C 11 Heterocycloalkyl. 3- The C7 cycloalkyl group may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, but is not limited thereto. Z may be, for example, unsubstituted or substituted with halogen, hydroxyl, cyano, nitro, amino, halogenated C 1- C4 alkyl, C 1-C4 alkoxy, hydroxyl 1- C4 alkyl or C 1- C4 alkyl substituted C 3- C7 cycloalkyl, but not limited thereto. 3- The C7 cycloalkyl group may be piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl or tetrahydrofuranyl, but is not limited thereto.
[0160] In the compound according to one embodiment, R 7 can be cyclopropyl and Z can be C 1- C4 alkyl substituted piperazinyl, for example dimethylpiperazinyl. The compounds according to the embodiments may have improved pharmacokinetic profiles and metabolic stability, such as microsomal stability.
[0161] In one embodiment, the compound of Formula 1 may be selected from the compound represented by Formula 14, and stereoisomers, tautomers, solvates or pharmaceutically acceptable salts thereof:
[0162] [Formula 14]
[0163]
[0164] Among them, in formula 14,
[0165] E a It can be hydrogen, hydroxyl or C 1- C4 alkoxy;
[0166] E b It can be hydrogen, halogen, C 1- C4 alkyl or C 1- C4 fluoroalkyl;
[0167] E c and E d may each independently be hydrogen or hydroxyl;
[0168] X' may be hydrogen or hydroxyl;
[0169] k can be an integer from 0 to 4;
[0170] Q can be independently hydroxyl, halogen, C 1- C4 alkyl, hydroxyl C 1- C4 alkyl or C 1- C4 alkoxy; and
[0171] Z' is a monovalent functional group which can be represented by Formula 15;
[0172] [Formula 15]
[0173]
[0174] Wherein, in formula 15, n can be an integer from 1 to 8;
[0175] A can be independently selected from hydroxyl, C 1- C4 alkyl and hydroxyl C 1- A functional group of C4 alkyl, wherein when n is two or more, two A's may be linked to each other to form an alkylene bridge to form a 7- to 12-membered bridged heterobicycloalkyl ring Z', or two A's may be spirally connected to form a 7- to 12-membered spiroheterocycloalkyl ring;
[0176] L can be hydrogen, C 1- C4 alkyl, hydroxyl or hydroxyl C 1- C4 alkyl.
[0177] Compounds selected from compounds of Formula 14 and stereoisomers, tautomers, solvates or pharmaceutically acceptable salts thereof may have improved properties compared to other compounds having similar chemical structures, in terms of pharmacokinetic profiles suitable for oral administration, and in terms of metabolic stability, such as microsomal stability.
[0178] The term "pharmacokinetic curve" as used herein refers to the absorption, distribution, in vivo changes and excretion curves of a drug. From the pharmacokinetic curve, the physiological and biochemical effects of the drug on the organism and its mechanism of action, that is, the response of the organism to the drug can be identified.
[0179] The term "metabolic stability" such as microsomal stability as used herein refers to the degree of stability of the metabolic organ after administration of the drug, and can affect the pharmacokinetic parameters of the drug, such as clearance, half-life and oral bioavailability. As an in vitro experiment to predict the extent of drug metabolism in major organs, metabolically active systems such as liver microsomes or hepatocytes can be used to measure metabolic stability.
[0180] In one embodiment, E b It may be a halogen, n may be an integer from 2 to 4, and A may be an alkyl group such as methyl, ethyl or propyl.
[0181] In one embodiment, E b may be halogen, n may be 2, and A may be methyl.
[0182] In one embodiment, Z' may be 3,5-dimethylpiperazin-1-yl.
[0183] In one embodiment, E b It may be chlorine.
[0184] Compounds selected from compounds of formula 14 and their stereoisomers, tautomers, solvates or their pharmaceutically acceptable salts can effectively control one or more kinases related to intracellular signaling and intracellular complex biological mechanisms. For example, the selected compound can act on receptor tyrosine kinase (RTK) to effectively control the intracellular delivery of extracellular stimulation. In one embodiment, the selected compound can effectively control the fms-like tyrosine kinase 3 (FLT3) often abnormally overexpressed or mutated in leukemia patients, and act on the signal pathway of endothelial growth factor receptor (VEGFR) and spleen tyrosine kinase (SYK) of other immune receptors (such as B cell receptor and mast cell), wherein endothelial growth factor receptor (VEGFR) is related to the control of angiogenesis process. According to a compound of one embodiment, the mutation or overexpression of FLT3 is effectively suppressed, and the overexpression or overactivation of VEGFR is suppressed simultaneously, so as to block the supply of nutrition and oxygen to the tumor and suppress SYK. Therefore, the compound can be useful for the treatment of acute myeloid leukemia (AML) showing resistance to FLT3 inhibitors. The term "overall survival (OV)" as used herein refers to the time period from random assignment to death in a clinical trial. FLT3-ITD positive acute myeloid leukemia (AML) is a disease with very low OV. SYK is overexpressed and activated in hematological malignancies, and highly activated SYK is usually found in FLT3-ITD positive acute myeloid leukemia (AML) with very low OV. Therefore, as a target for the treatment of AML diseases, SYK needs to be considered as an important factor together with FLT3.
[0185] The compound according to one embodiment shows potent and selective inhibitory activity against SYK and FLT3, thereby greatly improving the therapeutic effect of acute myeloid leukemia (AML) and increasing the OV time.
[0186] In one embodiment, L is hydrogen, C 1- C4 alkyl, hydroxyl or hydroxyl C 1- C4 alkyl;
[0187] E b is halogen, such as chlorine, n is 2, and A is methyl;
[0188] A compound selected from formula 14 compounds and stereoisomers, tautomers, solvates or pharmaceutically acceptable salts thereof (wherein Z' is 3,5-dimethylpiperazine-1-yl) show excellent inhibitory activity to FLT3, and can effectively inhibit the overexpression or overactivation of VEGFR and SYK. In addition, the compound can be effectively used to prevent or treat cell proliferative diseases caused by the abnormal activity of FLT3, VEGFR and SYK to enhance the tumor treatment effect. Therefore, the compound can be useful for treating cancers or leukemias such as AML that are resistant to the FLT3 inhibitors of the related art.
[0189] In one embodiment, the compound of Formula 1 may be a compound selected from the compounds listed in Table 1:
[0190] [Table 1]
[0191]
[0192]
[0193]
[0194] The term "isomer" as used herein refers to compounds having the same molecular formula and different structures. According to one aspect of the present disclosure, the compound of formula 1 can exist as various compounds having an isomeric relationship in three dimensions, and these isomers and mixtures are within the scope of the present disclosure. In one or more embodiments, the compound of formula 1 according to one aspect of the present disclosure can exist as stereoisomers or structural isomers, such as tautomers.
[0195] The term "stereoisomer" as used herein refers to compounds having the same molecular formula and the same sequence of atoms connected but differing in stereo or optical aspects. That is, stereoisomers refer to compounds having the same chemical composition but differing in three-dimensional arrangement, i.e., the arrangement of atoms or groups is different. Stereoisomers include geometric isomers, enantiomers, and partial stereoisomers.
[0196] The term "geometric isomer" as used herein refers to the type of stereoisomer depending on the orientation of the functional groups in the molecule, and may be referred to as cis-trans isomers. Generally, these isomers contain non-rotatable double bonds, and the substituents of the compound containing the double bond may be in the E form or the Z form. For example, when the compound contains a 2-substituted cycloalkyl, the compound may have a cis-trans form. When the compound of Formula 1 contains a bridged ring, the compound may exist as an exo- or endo-isomer.
[0197] The term "chirality" as used herein refers to a molecule with non-overlapping enantiomeric partners, while the term "achiral" as used herein refers to a molecule with overlapping enantiomeric partners. The term "enantiomer" as used herein refers to the situation where two molecules have optical activity and are mirror-symmetrical. That is, enantiomers represent isomers that do not overlap with the original molecule, and do not have any symmetry elements including a plane of symmetry and a center of symmetry, and have a stereocenter (chiral center). The term "diastereomer" as used herein refers to not enantiomers but stereoisomers in the case of molecules with two or more chiral centers. Since the compound of formula 1 according to one aspect of the present disclosure can have a chiral center or an asymmetric carbon center (no carbon), the compound can exist as an enantiomer (R or S isomer), a racemate, a diastereoisomer or a mixture thereof, and all these isomers and mixtures are included in the scope of the present disclosure. Optically active (R)- and (S)-isomers can be decomposed by using the technology of the relevant field or chiral synthons or chiral reagents.
[0198] The term "structural isomer" as used herein refers to isomers with the same molecular formula but different atomic connection sequences, and may include tautomerism. The term "tautomer" as used herein refers to structural isomers with different energy structures exchanged by low energy barriers. For example, photon tautomers (also proton tautomers) include interconversions by photon transfer, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by rearranging certain electrons in bound electrons. According to one aspect, the compound of formula 1 and its stereoisomers or tautomers may exist in the form of a solvate. The term "solvate" may include a molecular complex including the compound and at least one pharmaceutically acceptable solvent molecule, such as ethanol or water. The complex in which the solvent molecule is water is also referred to as a "hydrate".
[0199] According to one aspect, the compound of formula 1 and its stereoisomers, tautomers and solvates can exist in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" as used herein refers to a salt that has low toxicity to the human body and does not adversely affect the biological activity and physicochemical properties of the parent compound. Pharmaceutically acceptable salts include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts of the compound represented by formula 1, which are understood by those skilled in the art.
[0200] Pharmaceutically acceptable salts can be prepared by conventional methods. For example, the compound of Formula 1 can be dissolved in a solvent such as methanol, ethanol, acetone, 1,4-dioxane, which can be mixed with water, and then a free acid or free base can be added thereto for crystallization to prepare a pharmaceutically acceptable salt.
[0201] Another aspect of the present disclosure provides a method for preparing the compound.
[0202] According to another aspect of the present disclosure, there is provided a method for preparing a compound of Formula 1, the method comprising reacting a compound of Formula 6 with a compound of Formula 7:
[0203] [Formula 6]
[0204]
[0205] [Formula 7]
[0206]
[0207] Where R in formula 6 and 7 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, Y, Z and k may be the same as described with respect to Formulas 1 and 2, and V 2 It may be a halogen.
[0208] When carrying out the reaction, an organic base such as triethylamine, diisopropylethylamine and pyridine, etc., an inorganic base such as sodium carbonate, potassium carbonate and sodium hydride, etc., an organic acid such as trifluoroacetic acid and toluenesulfonic acid, etc., or an inorganic acid such as hydrochloric acid, sulfuric acid and phosphoric acid, etc., may or may not be added to the reaction solution. The solvent used in the reaction may be any solvent that does not inhibit the reaction, such as a polar aprotic solvent such as dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile or tetrahydrofuran (THF); a polar protic solvent such as methanol, ethanol, 2-propanol or 2-butanol; or a non-polar aprotic solvent such as toluene or 1,4-dioxane. The reaction temperature may be in the range of 0°C to 150°C, such as room temperature to about 100°C.
[0209] In an exemplary embodiment, the compound of Formula 1 can be prepared as shown in Reaction Scheme 1:
[0210] [Reaction Scheme 1]
[0211]
[0212] Compounds of Formula 4 and Formula 5 can be prepared by using conventional knowledge in the field of organic chemistry.
[0213] In reaction scheme 1, R 1 , R 2 , R 3 , R 4 , R 5 , R 6, R 7 , X, Y, Z and k may be the same as those defined in Formulas 1 and 2, respectively, and V 1 and V 2 Each may independently be a halogen.
[0214] When the compound of Formula 6 is prepared by reacting the compound of Formula 4 with the compound of Formula 5, the reaction may be performed by adding an organic metal compound. For example, the organic metal compound may be an alkyl magnesium compound or an alkyl lithium compound.
[0215] The solvent used in the reaction can be any solvent that does not inhibit the reaction, for example, a polar aprotic solvent such as dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile or THF, or a non-polar aprotic solvent such as toluene or 1,4-dioxane. The reaction temperature can be in the range of 0°C to 100°C, for example, 0°C to 60°C.
[0216] In preparing the compound of formula 7,
[0217] When Y is -(CH2) m -, m can be an integer from 1 to 2,
[0218] When Y is -(CH2) m -O-(CH2) n -, m may be 0 and n may be each independently an integer from 0 to 2,
[0219] When Y is -(CH2) m -CO-(CH2) n -, m and n can be 0 respectively, and
[0220] The compounds are prepared based on the general knowledge in the corresponding field of organic chemistry, as explained with respect to Preparation Schemes 1 to 3.
[0221] [Preparation Scheme 1]
[0222] When Y is -(CH2) m -In the case of:
[0223]
[0224] In Preparation Scheme 1, R 5 , R 6 , R 7 , R 9 , and q are the same as described with respect to Formula 1 and Formula 3, and V 3 It can be a halogen and L can be Cl, Br, I, OMs or OTs, etc.
[0225] [Preparation Scheme 2]
[0226] When Y is -(CH2) m -O-(CH2) n -In the case of:
[0227]
[0228] In Preparation Scheme 2, R 5 , R 6 , R 7 , R 9 , and q are the same as described with respect to Formula 1 and Formula 3, and L may be Cl, Br, I, OMs, or OTs.
[0229] [Preparation Scheme 3]
[0230] When Y is -(CH2) m -CO-(CH2) n -In the case of:
[0231]
[0232] In Preparation Scheme 3, R 5 , R 6 , R 7 , R 9 , and q are the same as described with respect to Formula 1 and Formula 3.
[0233] Another aspect of the present disclosure provides,
[0234] A method for preparing a compound represented by Formula 1a, the method comprising a compound represented by Formula 10 and a compound represented by Formula 3:
[0235] [Formula 10]
[0236]
[0237] [Formula 3]
[0238]
[0239] [Formula 1a]
[0240]
[0241] R in Equation 10, Equation 3, and Equation 1a 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , X, k, and q may be the same as described with respect to Formula 1, Formula 2, and Formula 3.
[0242] The reaction can be carried out by adding or not adding the following to the reaction solution: a reducing agent such as sodium borohydride, sodium cyanoborohydride and sodium triacetoxyborohydride, etc.; an organic base such as triethylamine, diisopropylethylamine and pyridine; an inorganic base such as sodium carbonate, potassium carbonate and sodium hydride; an organic acid such as trifluoroacetic acid and toluenesulfonic acid, etc.; or an inorganic acid such as hydrochloric acid, sulfuric acid and phosphoric acid. The solvent used in the reaction can be any solvent that does not inhibit the reaction, and examples of the solvent are polar aprotic solvents such as dichloromethane, 1,2-dichloroethane, dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile or tetrahydrofuran; polar protic solvents such as methanol, ethanol, 2-propanol or 2-butanol; and non-polar aprotic solvents such as toluene or 1,4-dioxane. The reaction temperature can be in the range of 0°C to 150°C, for example, room temperature.
[0243] Compounds of formula 10 can be prepared using conventional knowledge in the art of organic chemistry.
[0244] In one embodiment, the compound represented by Formula 1a can be prepared by using the method illustrated in Reaction Scheme 2.
[0245] [Reaction Scheme 2]
[0246]
[0247] In Reaction Scheme 2, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , X, k and q are the same as those described with respect to Formula 1, Formula 2 and Formula 3, and V 2 It is a halogen.
[0248] In order to prepare the compound of Formula 10 from the compound of Formula 9, the compound of Formula 9 is oxidized using an oxidizing agent such as MnO 2 , and then washed with an organic solvent such as dichloromethane, followed by concentrating and purifying the resulting organic layer.
[0249] The compound of formula 9 is prepared by reacting the compound of formula 8 with the compound of formula 6, and the solvent used in the reaction can be any solvent that does not inhibit the reaction. For example, the reaction can be carried out by adding or not adding the following to the reaction solution: organic bases such as triethylamine, diisopropylethylamine and pyridine; inorganic bases such as sodium carbonate, potassium carbonate and sodium hydride; organic acids such as trifluoroacetic acid and toluenesulfonic acid, etc.; or inorganic acids such as hydrochloric acid, sulfuric acid and phosphoric acid, and the base or acid equivalent can be 0.1 to 5 equivalents, based on 1 equivalent of formula B compound 1. The solvent used in the reaction can be a polar aprotic solvent such as dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile, or tetrahydrofuran, etc.; a polar protic solvent such as methanol, ethanol, 2-propanol or 2-butanol; or a non-polar aprotic solvent such as toluene or 1,4-dioxane. The reaction temperature can be in the range of 0°C to 150°C, for example, 50°C to about 100°C.
[0250] Although the method for preparing Formula 1 has been described by way of specific examples, specific reaction conditions, such as the reaction solvent, base and amount of reactants used are not limited to those described in this specification and should not be construed as limiting the scope of the present disclosure.
[0251] Another aspect of the present disclosure provides a pharmaceutical composition for preventing or treating cancer, the composition comprising the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
[0252] The cancer may include leukemia, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), acute promyelocytic leukemia (APL), hairy cell leukemia, or chronic neutrophilic leukemia (CNL), among others.
[0253] In one embodiment, the cancer may be leukemia.
[0254] In one embodiment, the leukemia may include AML, ALL, or CML.
[0255] Another aspect of the present disclosure provides a pharmaceutical composition for preventing or treating a FLT3-mediated disease, the composition comprising the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
[0256] Another aspect of the present disclosure provides a pharmaceutical composition for inhibiting FLT3 kinase activity, the pharmaceutical composition comprising a compound according to one aspect or a pharmaceutically acceptable salt thereof, and a pharmacologically acceptable excipient.
[0257] In an exemplary embodiment, the pharmaceutical composition may include a pharmaceutically acceptable excipient or additive. The pharmaceutical composition of the present disclosure may be prepared according to conventional methods and may be formulated into various oral dosage forms, such as tablets, pills, powders, capsules, syrups, emulsions, and microemulsions; or non-oral dosage forms, such as intramuscular injection, intravenous injection, or subcutaneous injection.
[0258] When the pharmaceutical composition of the present disclosure is prepared in the form of an oral formulation, examples of the carrier or additive used include diluents, disintegrants, adhesives, lubricants, surfactants, suspensions and emulsifiers. When the pharmaceutical composition of the present disclosure is prepared in the form of an injection, examples of the carrier or additive can include water, saline solution, glucose solution, pseudosugar solution, alcohol, ethylene glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride, surfactant, suspension and emulsifier. Such preparation methods are well known to those of ordinary skill in the pharmaceutical field.
[0259] In one embodiment, as an active ingredient included in a pharmaceutical composition, the compound of Formula 1 can be administered to a subject or patient in an effective amount for treatment or prevention. Depending on the purpose, the compound of Formula 1 can be administered orally or non-orally. When the compound is administered orally, the active ingredient can be administered in an amount ranging from 0.01 milligrams (mg) to 1000 milligrams per kilogram of body weight per day, for example, 0.01 mg to 500 mg, for example, 0.1 mg to 300 mg, for example, 0.1 to 100 mg. When the compound is administered non-orally, the active ingredient can be administered once to several times, with an amount ranging from 0.01 mg to 100 mg per kilogram of body weight per day, for example, 0.1 mg to 50 mg. The composition can be administered all at once or in several doses. The dosage for a subject or patient should be determined according to the patient's weight, age, sex, health condition, diet, administration time, administration method, disease severity, etc. It is understood that the dosage can be appropriately adjusted by the practitioner. The dosage is not intended to limit the scope of the present disclosure in any aspect.
[0260] Another aspect of the present disclosure provides a method for preventing or treating cancer by using a compound according to this aspect. In one embodiment, the method may include administering a compound selected from the compound of Formula 1 according to one aspect, and a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof to a subject. The subject may be a patient. Another aspect of the present disclosure provides a method for inhibiting the FLT3 activity of a target subject by using a compound according to this aspect.
[0261] Another aspect of the present disclosure provides a method of treating a FLT3-mediated disease by using a compound according to this aspect.
[0262] The details of the preventive or therapeutic method may be the same as described above with reference to the pharmaceutical composition according to an aspect of the present disclosure.
[0263] In one embodiment, the dosage, number of administrations or method of administration of the compound for treatment may vary depending on the severity of the subject to be treated, the disease or condition, the speed of administration and the judgment of the prescribing physician. The dosage of a person weighing 70 kg may be within the range of 0.1 to 2000 mg per day, such as 1 to 1000 mg or 10 to 2000 mg. The number of administrations may be administered once to several times, such as 1 to 4 times or according to an on / off schedule, and the method of administration may be administered orally or non-orally. In one or more embodiments, the dosage may be less than the above range. In one or more embodiments, the dosage may be greater than the above range without causing harmful side effects. In the latter case, the dosage may be administered in several small portions throughout the day. A physician with ordinary skills in the relevant field may determine and prescribe the dosage of the compound according to the purpose. For example, a physician may use a compound according to an embodiment of the present disclosure in an amount lower than the dosage required to achieve the target therapeutic effect, and then gradually increase the dosage until the target effect is obtained.
[0264] In one embodiment, according to the method, the compound according to one aspect of the present disclosure can be used alone as an active ingredient, or in combination with one or more other pharmaceutical drugs or pharmaceutical carriers known to treat cancer, tumors or leukemia. In one embodiment, a compound selected from the compounds represented by Formula 1, and its stereoisomers, tautomers, solvates or pharmaceutically acceptable salts can be administered together with other FLT3 kinase activity inhibitors or other agents that improve the inhibitory effect of FLT3 kinase activity or exhibit various mechanisms of synergy to reduce FLT3 activity or enhance the therapeutic effect of FLT3-mediated diseases.
[0265] The term "treatment" as used herein includes treatment, amelioration, improvement or management of a disease. The term "treating" or "treatment" as used herein refers to inhibiting a disease, e.g., inhibiting a disease, condition or disorder, preventing further development of a pathology and / or symptom, ameliorating a disease or reversing a pathology and / or symptom, e.g., reducing the severity of a disease in a subject experiencing or displaying the pathology or symptom of a disease, condition or disorder.
[0266] As used herein, the terms "preventing" or "prevention" refer to disease prevention, e.g., preventing a disease, condition or disorder in a subject that may be susceptible to the disease, condition or disorder but does not yet experience or exhibit disease pathology or symptoms.
[0267] As used herein, the term "subject" or "patient" refers to any animal, including mammals, such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses or primates, and humans.
[0268] The terms “have”, “may have”, “include” or “may include” may refer to the presence of features (eg, components such as numbers, components, etc.) but do not exclude the presence of additional features.
[0269] Hereinafter, the present disclosure will be described in more detail by referring to the following embodiments and experimental examples. However, the embodiments and experimental examples are intended to help understand the present disclosure, and the scope of the present disclosure is not limited thereto in any sense.
[0270] Example 1: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-amine
[0271] Process 1) Preparation of 3-bromo-5-nitrobenzoic acid
[0272]
[0273] 500 g (2991.86 mmol) of 3-nitrobenzoic acid was dissolved in 1.4 L of concentrated (concentrated) sulfuric acid (H2SO4), and the temperature was raised to 60°C. 652 g (3590.23 mmol) of N-bromosuccinimide was added thereto three times for 1 hour, and the result was stirred at 60°C for 2 hours. Once the reaction was complete, ice was added to the reaction mixture. The resulting solid was obtained by filtration and dried in an oven at 40°C for 16 hours to obtain 730 g of the target compound with a yield of 99.2%.
[0274] 1 H-NMR (300MHz, DMSO-d6): δ8.59(s,1H),8.51(s,1H),8.38(s,1H).
[0275] Process 2) Preparation of (3-bromo-5-nitrophenyl)methanol
[0276]
[0277] 200 g (812.94 mmol) of 3-bromo-5-nitrobenzoic acid prepared in process 1) was dissolved in 1.25 L of tetrahydrofuran (THF), and the temperature was lowered to 0° C. 1.6 L (3251.76 mmol) of borane-dimethyl sulfide (2.0 M dissolved in THF) was slowly added dropwise thereto for 1.5 hours. The mixture was stirred at room temperature for 16 hours, and then stirred at 80° C. temperature under reflux for 1 hour. Once the reaction was completed, the resultant was cooled to room temperature, and saturated sodium bicarbonate was added dropwise thereto. Three extraction processes were performed on it using ethyl acetate, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified using column chromatography (chloromethylene: methanol = 10: 1 (v / v)), and the obtained solution was concentrated under reduced pressure, and then crystallized using hexane to obtain 180 g of the target compound with a yield of 95.4%.
[0278] 1 H-NMR (300MHz, DMSO-d6): δ8.23(s,1H),8.17(s,1H),7.96(s,1H),4.63(s,2H).
[0279] Process 3) Preparation of (3-cyclopropyl-5-nitrophenyl)methanol
[0280]
[0281] 100 g (431.00 mmol) of (3-bromo-5-nitrophenyl)methanol prepared according to process 2) and 111 g (1293.00 mmol) of cyclopropyl borate, 9.7 g (43.10 mmol) of Pd(OAc)2, 274.5 g (1293.00 mmol) of potassium phosphate and 33.92 g (129.30 mmol) of triphenylphosphine were dissolved in a mixed solvent of toluene and H2O (2:1, 1.35 L), and then flushed with nitrogen for 5 minutes. The reaction mixture was sealed, and the temperature was raised to 100°C, followed by stirring under reflux for 20 hours. Once the reaction was complete, the mixed solution was cooled to room temperature and filtered using a diatomaceous earth filter. The diatomaceous earth layer was washed with ethyl acetate. The organic layer was extracted three times from the filtered mixed solution, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified using column chromatography (ethyl acetate:hexane=1:5 (v / v)), and the obtained solution was concentrated under reduced pressure to obtain 62 g of the target compound with a yield of 74.5%.
[0282] 1H-NMR (300MHz, DMSO-d6): δ8.07(s,1H),7.71(s,1H),7.25(s,1H),4.70(s,2H),1.90(m,1H),1.01(m,2H),0.71(m,2H).
[0283] Process 4) Preparation of (3R,5S)-1-(3-cyclopropyl-5-nitrobenzyl)-3,5-dimethylpiperazine
[0284]
[0285] 2 g (10.35 mmol) of (3-cyclopropyl-5-nitrophenyl)methanol prepared according to process 3) was dissolved in a mixed solvent (1:1, 66 mL) including tetrahydrofuran and water, and the temperature was lowered to 0°C. Sodium hydroxide (NaOH; 829 mg, 20.70 mmol) and 3.95 g (20.70 mmol) of p-toluenesulfonyl chloride were added thereto. After stirring at a temperature of 0°C for 1 hour, water was added dropwise thereto at room temperature. Three extraction processes were performed thereon using ethyl acetate, and the organic layer was washed with brine, dried using anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in 11 mL of N,N-dimethylformamide, and 796 mg (5.76 mmol) of potassium carbonate (K2CO3) and 394 mg (3.45 mmol) of (2R,6S)-2,6-dimethylpiperazine were added thereto, and the resulting mixture was stirred at reflux at a temperature of 100°C for 1 hour. Once the reaction is complete, the mixed solution is cooled to room temperature, and ethyl acetate and water are added dropwise thereto. The organic layer is extracted therefrom, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue is purified using MPLC (chloroform: methanol = 10: 1 (v / v)), and the resulting solution is concentrated under reduced pressure to obtain 645 mg of the target compound with a yield of 77%.
[0286] 1 H-NMR (300MHz, CDCl3): δ7.95(s,1H),7.76(s,1H),7.37(s,1H),3.53(m,2H),3.44(t,4H),2.39(t,4H),1.45(m,9H),1.04(m,2H),0.76(m,2H).
[0287] Process 5) Preparation of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline
[0288]
[0289] 11 mL of 50% ethanol was added to 622 mg (11.14 mmol) of Fe powder, and 0.1 mL (0.89 mmol) of concentrated hydrochloric acid (conc. HCl) was slowly added dropwise thereto, and the resulting mixture was stirred at reflux at a temperature of 110° C. for 1.5 hours. (3R, 5S)-1-(3-cyclopropyl-5-nitrobenzyl)-3,5-dimethylpiperazine (645 mg, 2.23 mmol) prepared according to process 4) was added to the activated Fe mixture, and the resulting mixture was stirred at reflux at a temperature of 110° C. for 1 hour. Once the reaction was completed, a diatomaceous earth filter was used to perform a filtration process on it. A mixed solution of chloroform and methanol and a saturated sodium bicarbonate solution were added dropwise to the filtrate. The organic layer was separated from the mixture solution, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 518 mg of the target compound with a yield of 90%.
[0290] Process 6) Preparation of 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)benzene yl)-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-amine
[0291]
[0292] 46 mg (0.17 mmol) of 3-cyclopropyl-5-(((3R, 5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline prepared according to process 5) and 50 mg (0.17 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole (the preparation method thereof is disclosed in WO2013014448) were dissolved in 2 mL of 2-butanol, and 34 mg (0.17 mmol) of p-toluenesulfonic acid (p-TsOH) were added thereto. The reaction mixture was stirred at reflux at a temperature of 120° C. for 21 hours. Once the reaction was complete, the mixture was cooled to room temperature, and a saturated sodium bicarbonate solution was added dropwise thereto, followed by two extraction processes using chloroform. The extracted organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified using column chromatography (chloroform:methanol=9:1 (v / v)), and the obtained solution was concentrated under reduced pressure to obtain 11 mg of the target compound with a yield of 12%.
[0293] MS (ESI + ,m / z):505[M+H] +
[0294] 1H-NMR (300MHz, DMSO-d6): δ11.94(bs,1H),9.50(s,1H),8.60(m,1H),8.50(s,1H),8.44(s,1H),7.43(s,1H),7.3 6(s,1H),7.29(m,1H),6.96(m,1H),6.63(s,1H),2.70(m,4H),1.85(m,1H),1.44(m,2),0.92(m,8H),0.60(m,2H).
[0295] Example 2: 5-Chloro-4-(6-chloro-1H-indol-3-yl)-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-amine
[0296]
[0297] 97 mg of the target compound was obtained in a 69% yield in essentially the same manner as in process 6) of Example 1, except that 89 mg (0.30 mmol) of 6-chloro-3-(2,5-dichloropyrimidin-4-yl)-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole in process 6) of Example 1.
[0298] MS (ESI + ,m / z):521[M+H] +
[0299] 1 H-NMR (300MHz, DMSO-d6): δ12.01(s,1H),9.54(s,1H),8.58(d,1H),8.54(s,1H),8.46(s,1H),7.55(m,1H),7.46(m,1H),7.36(s,1H) ,7.11(m,1H),6.65(s,1H),3.37(s,2H),2.85(m,2H),2.71(d,2H),1.84(m,1H),1.60(m,2H),0.95(d,7H),0.89(m,2H),0.61(m,2H).
[0300] Example 3: 2-((2R,6S)-4-(3-((5-chloro-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol
[0301]
[0302] 38 mg of the target compound was obtained in a 63% yield in essentially the same manner as process 6) of Example 1, except that 32 mg (0.11 mmol) of 2-((2R,6S)-4-(3-amino-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethane-1-ol was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline.
[0303] MS (ESI + ,m / z):549[M+H] +
[0304] 1 H-NMR (300MHz, DMSO-d6): δ11.94(bs,1H),9.51(s,1H),8.59(m,1H),8.54(m,1H),8.49(s,1H),7.42(s,3H),7.36(s,1H),7.27(d,1H ),6.96(t,1H),6.62(s,1H),4.35(m,1H),3.39(m,4H),3.27(m,2H),2.48(m,4H),1.82(m,1H),1.59(m,2H),0.89(m,8H),0.57(m,2H).
[0305] Example 4: 2-((2R,6S)-4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol
[0306]
[0307] 18 mg of the target compound was obtained in a 31% yield in essentially the same manner as process 6) of Example 1, except that 32 mg (0.11 mmol) of 2-((2R,6S)-4-(3-amino-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethane-1-ol was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 31 mg (0.11 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0308] MS (ESI+, m / z): 531 [M+H] +
[0309] 1H-NMR (300MHz, DMSO-d6): δ11.90(bs,1H),9.48(s,1H),8.57(d,1H),8.54(m,1H),8.47(s,1H),7.49(m,3H),7.23(m,1H),7.18 (m,1H),6.61(s,1H),4.35(m,1H),3.39(m,4H),3.27(m,2H),2.48(m,4H),1.82(m,1H),1.59(m,2H),0.89(m,8H),0.59(m,2H).
[0310] Example 5: 2-((2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol
[0311]
[0312] 28 mg of the target compound was obtained in a 47% yield in essentially the same manner as process 6) of Example 1, except that 32 mg (0.11 mmol) of 2-((2R,6S)-4-(3-amino-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethane-1-ol was used instead of 3-cyclopropyl-5-((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 31 mg (0.11 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0313] MS (ESI+, m / z): 545 [M+H] +
[0314] 1 H-NMR (300MHz, DMSO-d6): δ11.76(bs,1H),9.45(s,1H),8.45(m,3H),7.43(d,1H),7.25(s,1H),6.94(d,1H),6.61(s,1H ),4.35(m,1H),3.39(m,4H),3.27(m,2H),2.48(m,4H),2.40(s,3H),1.82(m,1H),1.59(m,2H),0.89(m,8H),0.59(m,2H).
[0315] Example 6: (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine
[0316]
[0317] 32 mg of the target compound was obtained in a 17% yield in essentially the same manner as process 6) of Example 1, except that 100 mg (0.41 mmol) of (R)-3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)aniline was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 108 mg (0.41 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0318] MS (ESI+, m / z): 473 [M+H] +
[0319] 1 H-NMR (300MHz, DMSO-d6): δ11.93(s,1H),9.52(s,1H),8.58(d,1H),8.50 (d,1H),8.46(s,1H),7.54(m,3H),7.22(t,1H),7.15(m,1H),6.65(s,1H) ,3.77(m,1H),3.45(m,2H),3.21(m,2H),2.95(m,1H),2.82(m,2H),2.28( s,3H),2.20(m,1H),2.01(m,1H),1.84(m,1H),0.93(m,2H),0.63(m,2H).
[0320] Example 7: (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0321]
[0322] 39 mg of the target compound was obtained in a 38% yield in essentially the same manner as process 6) of Example 1, except that 53 mg (0.21 mmol) of (R)-3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)aniline was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 66 mg (0.24 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0323] MS (ESI+, m / z): 487 [M+H] +
[0324] 1 H-NMR (300MHz, DMSO-d6): δ11.77(bs,1H),9.47(s,1H),8.47(m,3H),7.50(s,1H),7.39(s,1H),7.28(s,1H),6.93(d,1H ),6.64(s,1H),3.39(s,2H),2.94(m,1H),2.77(m,2H),2.42(s,3H),2.00(m,5H),1.04(m,4H),0.92(m,2H),0.62(m,2H).
[0325] Example 8: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0326]
[0327] 30 mg of the target compound was obtained in a 7% yield in essentially the same manner as in process 6) of Example 1, except that 222 mg (0.80 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole in process 6 of Example 1.
[0328] MS (ESI+, m / z): 501 [M+H] +
[0329] 1 H-NMR (300MHz, DMSO-d6): δ11.76(bs,1H),9.45(s,1H),8.47(m,3H),7.46(s,1H),7.39(s,1H),7.27(s,1H),6.96 (d,1H),6.63(s,1H),2.69(m,2H),2.60(m,2H),2.42(s,3H),1.84(m,1H),1.45(t,2H),0.91(m,8H),0.62(m,2H).
[0330] Example 9: 5-Chloro-N-(3-cyclopropyl-5-(((3S,5R)-3-ethyl-5-methylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0331]
[0332] 30 mg of the target compound was obtained in a 29% yield in essentially the same manner as process 6) of Example 1, except that 55 mg (0.20 mmol) of 3-cyclopropyl-5-(((3S,5R)-3-ethyl-5-methylpiperazin-1-yl)methyl)aniline was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 61 mg (0.22 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0333] MS (ESI+, m / z): 515 [M+H] +
[0334] 1 H-NMR (300MHz, DMSO-d6): δ11.77(bs,1H),9.45(s,1H),8.47(m,3H),7.46(s,1H),7.39(s,1H),7.27(s,1H),6.96 (d,1H),6.63(s,1H),3.36(m,2H),2.70(m,4H),2.42(s,3H),1.85(m,1H),1.50(m,2H),0.93(m,11H),0.61(m,2H).
[0335] Example 10: 5-Chloro-N-(3-cyclopropyl-5-((3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0336]
[0337] 100 mg of the target compound was obtained in a 52% yield in essentially the same manner as process 6) of Example 1, except that 100 mg (0.36 mmol) of 3-cyclopropyl-5-((3,5-dimethylpiperazin-1-yl)methyl)aniline was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 150 mg (0.54 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0338] MS (ESI+, m / z): 501 [M+H] +
[0339] 1H-NMR (300MHz, DMSO-d6): δ11.77(s,1H),9.46(s,1H),8.45(m,3H),7.43(d,2H),7.30(s,1H),6.75(d,1H) ,6.64(s,1H),2.82(m,2H),2.72(d,2H),2.42(s,3H),1.83(m,1H),1.47(t,1H),0.88(s,8H),0.64(m,2H).
[0340] Example 11: N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0341]
[0342] 409 mg of the target compound was obtained in a 31% yield in essentially the same manner as process 6) of Example 1, except that 700 mg (2.80 mmol) of 3-(2-chloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0343] MS (ESI+, m / z): 467 [M+H] +
[0344] 1 H-NMR (300MHz, DMSO-d6): δ11.63(bs,1H),9.20(s,1H),8.44(d,1H),8.2 8(d,1H),8.19(m,1H),7.51(s,1H),7.44(s,1H),7.22(m,2H),6.96(d,1H ),6.59(s,1H),4.20(m,1H),3.15(s,3H),2.71(m,2H),2.65(m,3H),2.40 (s,3H),1.85(m,1H),1.48(m,2H),0.93(m,2H),0.90(m,6H),0.62(m,2H).
[0345] Example 12: N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-fluoro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0346]
[0347] 101 mg of the target compound was obtained in a 77% yield in essentially the same manner as process 6) of Example 1, except that 78 mg (0.30 mmol) of 3-(2-chloro-5-fluoropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0348] MS (ESI + ,m / z):485[M+H] +
[0349] 1 H-NMR (300MHz, DMSO-d6): δ11.83(s,1H),9.36(s,1H),8.60(d,1H),8.40(d,1H),8.10(s,1H),7.48(s,1H),7.40(s,1H),7.29(s,1H),7.00 (d,1H),6.62(s,1H),3.42(s,2H),2.98(m,2H),2.79(d,2H),2.43(s, 3H),1.87(m,1H),1.70(m,2H),1.08(d,7H),0.96(m,2H),0.67(m,2H).
[0350] Example 13: N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)-5-methylpyrimidin-2-amine
[0351]
[0352] 99 mg of the target compound was obtained in a 79% yield in essentially the same manner as process 6) of Example 1, except that 73 mg (0.30 mmol) of 3-(2-chloro-5-methylpyrimidin-4-yl)-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0353] MS (ESI+, m / z): 467 [M+H] +
[0354] 1H-NMR (300MHz, DMSO-d6): δ11.74(s,1H),9.15(s,1H),8.58(d,1H),8.27(s,1H),8.00(d,1H),7.55(m,3H),7.20(t,1H),7.12(m,1H) ,6.56(s,1H),3.37(s,2H),2.86(m,2H),2.70(d,2H),2.37(s,3H),1.75(m,1H),1.57(m,2H),0.95(d,7H),0.91(m,2H),0.60(m,2H).
[0355] Example 14: N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-methyl-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0356]
[0357] 135 mg of the target compound was obtained in a 73% yield in essentially the same manner as process 6) of Example 1, except that 150 mg (0.58 mmol) of 3-(2-chloro-5-methylpyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0358] 1 H-NMR (300MHz, DMSO-d6): δ11.64(s,1H),9.15(s,1H),8.44(d,1H),8.25 (s,1H),7.92(d,1H),7.60(s,1H),7.45(s,1H),7.26(s,1H),7.12(s,1H) ,6.93(d,1H),6.58(s,1H),3.46(s,2H),2.83(d,2H),2.43(s,3H),2.36( s,3H),1.94(t,2H),1.91(m,1H),1.05(t,1H),0.89(m,2H),0.61(t,2H).
[0359] Example 15: N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-amine
[0360]
[0361] 289 mg of the target compound was obtained in a 28% yield in essentially the same manner as process 6) of Example 1, except that 600 mg (1.92 mmol) of 3-(2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0362] MS (ESI+, m / z): 535 [M+H] +
[0363] 1 H-NMR (300MHz, DMSO-d6): δ11.63(bs,1H),9.87(s,1H),8.69(s,1H),8.28(m,1H),7.77(s,1H),7.49(s,1H),7.39(s,1H),7.26(s,1H),6.93 (d,1H),6.66(s,1H),4.20(m,1H),3.15(s,3H),2.58(m,3H),2.55(m, 3H),2.40(s,3H),1.85(m,1H),1.40(m,2H),0.89(m,8H),0.57(m,2H).
[0364] Example 16: (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-6-yl)methanol
[0365] Process 1) Preparation of (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl) (phenyl)amino)pyrimidin-4-yl)-1-(p-toluenesulfonyl)-1H-indol-6-yl)methanol
[0366]
[0367] 30 mg of the target compound was obtained in a 46% yield in essentially the same manner as process 6) of Example 1, except that 51 mg (0.11 mmol) of (3-(2,5-dichloropyrimidin-4-yl)-1-tosyl-1H-indol-6-yl)methanol was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0368] 1H-NMR (300MHz, DMSO-d6): δ9.70(s,1H),8.62(s,1H),8.58(s,1H),8.29-8.03(m,2H),7.53-7.09(m,4H),6.33(s,1H),5 .39(brs,1H),4.65(s,2H),2.73(m,2H),2.61(d,2H),2.33(s,3H),1.80(m,1H),1.49(t,1H),0.88(m,10H),0.55(m,2H).
[0369] Process 2) Preparation of (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl) phenyl)amino)pyrimidin-4-yl)-1H-indol-6-yl)methanol
[0370]
[0371] 18 mg (0.03 mmol) of (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-1-tosyl-1H-indol-6-yl)methanol prepared according to process 1) of Example 16 was dissolved in a mixed solvent (1 mL, 1:1) including methanol and tetrahydrofuran, and then the temperature was increased to 60°C. 18 mg (0.06 mmol) of cesium carbonate was added thereto, and the resulting mixture was stirred at 60°C for 2 hours. Once the reaction was completed, the temperature was lowered to room temperature and an aqueous ammonium chloride solution was added thereto. An extraction process was performed thereon three times using chloroform. The result was dried using anhydrous sodium sulfate and then concentrated under reduced pressure. The obtained residue was purified using medium pressure liquid chromatography (MPLC) (chloroform:methanol=100:5 (v / v)), and the obtained solution was concentrated under reduced pressure to obtain 10 mg of the target compound with a yield of 72%.
[0372] MS (ESI+, m / z): 517 [M+H] +
[0373] 1 H-NMR (300MHz, DMSO-d6): δ11.90(s,1H),9.49(s,1H),8.51(m,3H),7.48(s,1H),7.46(s,1H),7.39(s,1H),7.07(d,1H),6.65(s,1H) ,5.19(m,1H),4.62(s,2H),4.14(m,1H),3.46(s,2H),3.16(m,2H),2.83(d,2H),1.945(m,4H),1.11(d,2H),0.93(m,4H),0.64(m,2H).
[0374] Example 17: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(5-methoxy-6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0375]
[0376] 11 mg of the target compound was obtained in a 13% yield in essentially the same manner as process 6) of Example 1, except that 50 mg (0.16 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-5-methoxy-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0377] MS (ESI+, m / z): 531 [M+H] +
[0378] 1 H-NMR (300MHz, DMSO-d6): δ11.64(s,1H),9.45(s,1H),8.41(s,1H),8.27(s,1H),7.85(s,1H),7.38(m,2H),7.22(s,1H),6.61(s,1H) ,3.50(s,3H),2.72(m,2H),2.65(m,2H),2.27(m,4H),1.65(m,1H),1.59(m,2H),1.21(m,2H),1.07(m,6H),0.82(m,2H),0.51(m,2H).
[0379] Example 18: 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-6-methyl-1H-indol-5-ol
[0380]
[0381] 10 mg of the target compound was obtained in a 15% yield in essentially the same manner as process 6) of Example 1, except that 39 mg (0.13 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indol-5-ol was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0382] MS (ESI+, m / z): 517 [M+H] +
[0383] 1H-NMR (300MHz, DMSO-d6): δ11.50(s,1H),9.31(s,1H),8.56(s,1H),8.30(s,1H),8 .15(s,1H),7.78(s,1H),7.60(s,1H),7.40(s,1H),7.16(s,1H),6.58(s,1H),3.17 -2.56(m,4H),2.26(m,3H),1.89(m,1H),1.22(m,2H),0.86(m,8H),0.57(m,2H).
[0384] Example 19: 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-6-methylindolin-2-one
[0385]
[0386] 5 mg of the target compound was obtained in a 3% yield in essentially the same manner as process 6) of Example 1, except that 70 mg (0.24 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methylindol-2-one was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0387] MS (ESI+, m / z): 517 [M+H] +
[0388] 1 H-NMR (300MHz, DMSO-d6): δ10.65(s,1H),9.68(s,1H),8.57(s,1H),7.21(m,2H),7.09(m,1H),6.96(m,2H),6.56(s,1H) ,5.12(s,1H),2.82(m,2H),2.72(m,2H),2.27(s,3H),1.73(m,3H),1.17(m,3H),1.08(m,6H),0.90(m,2H),0.52(m,2H).
[0389] Example 20: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-methoxy-6-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0390]
[0391] 17 mg of the target compound was obtained in a 17% yield in essentially the same manner as process 6) of Example 1, except that 60 mg (0.19 mmol) of 3-(2,5-dichloro-6-methoxypyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0392] MS (ESI+, m / z): 531 [M+H] +
[0393] 1 H-NMR (300MHz, DMSO-d6): δ11.66(s,1H),9.41(s,1H),8.44(d,1H),8.32(s,1H),7.59(s,1H),7.40(s,1H),7.25(s,1H),6.95(d,1H) ,6.67(s,1H),4.04(s,3H),3.43(s,2H),2.98(m,2H),2.83(m,2H),2.45(s,3H),1.83(m,3H),1.08(m,6H),0.93(m,2H),0.64(m,2H).
[0394] Example 21: 5-Chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)-6-(6-methyl-1H-indol-3-yl)pyrimidin-4-ol
[0395]
[0396] 19 mg (0.04 mmol) of 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-methoxy-6-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine prepared according to Example 20 was dissolved in 1 mL of ethanol, and then 0.2 mL of hydrochloric acid was added thereto, followed by stirring at a temperature of 80° C. for 16 hours. Once the reaction was completed, the mixture was cooled to room temperature, and then ethyl acetate and saturated sodium bicarbonate were added thereto. An organic layer was separated therefrom, which was then dried using anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified using column chromatography (chloroform:methanol=5:1 (v / v)), and the resulting solution was concentrated under reduced pressure, thereby obtaining 1.4 mg of the target compound in a yield of 7%.
[0397] MS (ESI+, m / z): 517 [M+H] +
[0398] 1H-NMR (300MHz, DMSO-d6): δ11.56(s,1H),8.17(m,1H),8.06(d,1H),7.41(s,1H),7.32(s,1H),7.23(s,1H),6.82 (d,1H),6.70(s,1H),2.72(m,2H),2.50(m,2H),2.00(s,3H),1.83(m,3H),1.23(m,6H),0.93(m,2H),0.64(m,2H).
[0399] Example 22: 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-6-methyl-1H-indol-7-ol
[0400]
[0401] 25 mg of the target compound was obtained in a 41% yield in essentially the same manner as process 6) of Example 1, except that 50 mg (0.17 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indol-7-ol was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0402] MS (ESI+, m / z): 517 [M+H] +
[0403] 1 H-NMR (300MHz, DMSO-d6): δ11.50(bs,1H),9.45(s,1H),8.95(bs,1H),8.41(s,1H),8.35(s,1H),7.99(d,1H),7.46(s,1H),7.39(s,1H) ),6.85(d,1H),6.62(s,1H),3.34(s,2H),2.73(m,2H),2.63(m,2H),2.28(s,3H),1.83(m,1H),1.44(t,2H),0.92(m,9H),0.61(m,2H).
[0404] Example 23: 2-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol
[0405]
[0406] 5 mg of the target compound was obtained in a 5% yield in essentially the same manner as process 6) of Example 1, except that 56 mg (0.20 mmol) of 2-amino-4-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 85 mg (0.31 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0407] MS (ESI+, m / z): 517 [M+H] +
[0408] 1 H-NMR (300MHz, DMSO-d6): δ11.72(s,1H),8.38(m,2H),8.15(d,1H),8.08(s,1H),7.55(s,1H),7.22(s,1H),6.82(d,1H) ,6.50(s,1H),3.60(s,2H),2.70(d,4H),2.46(s,3H),1.74(m,1H),1.63(t,2H),0.84(d,6H),0.79(m,2H),0.50(m,2H).
[0409] Example 24: 4-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol
[0410]
[0411] 200 mg of the target compound was obtained in a 53% yield in essentially the same manner as process 6) of Example 1, except that 200 mg (0.73 mmol) of 4-amino-2-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 303 mg (1.09 mmol) of 3-(2-chloro-5-methylpyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0412] MS (ESI+, m / z): 517 [M+H] +
[0413] 1H-NMR (300MHz, DMSO-d6): δ11.72(s,1H),11.05(s,1H),9.09(s,1H),8.40-8.32(m,4H),7.26(s,2H),6.84(m, 2H),3.59(m,2H),2.77(d,4H),2.41(s,3H),2.11(m,1H),1.60(t,2H),0.92(d,6H),0.87(m,2H),0.58(m,2H).
[0414] Example 25: (R)-5-chloro-N-(3-cyclopropyl-5-((3,3,5-trimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0415] Process 1) (3-amino-5-cyclopropylphenyl)methanol
[0416]
[0417] 5.8 mg of the target compound was obtained in a 95% yield in essentially the same manner as process 5) of Example 1, except that 7.2 g (37.27 mmol) of (3-cyclopropyl-5-nitrophenyl)methanol was used instead of (3R,5S)-1-(3-cyclopropyl-5-nitrobenzyl)-3,5-dimethylpiperazine.
[0418] 1 H-NMR (300MHz, DMSO-d6): δ6.31(s,1H),6.18(s,1H),6.13(s,1H),4.94(m,3H),4.28(d,2H),1.73(m,1H),0.87(m,2H),0.56(m,2H).
[0419] Process 2) (3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylphenyl) Methanol
[0420]
[0421] 3.5 mg of the target compound was obtained in a 49% yield in essentially the same manner as process 6) of Example 1, except that 2.9 g (17.77 mmol) of (3-amino-5-cyclopropylphenyl)methanol was used instead of 3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)aniline, and 7.4 g (26.65 mmol) of 3-(2,5-dichloropyrimidin-4-yl)-6-methyl-1H-indole was used instead of 3-(2,5-dichloropyrimidin-4-yl)-6-fluoro-1H-indole.
[0422] 1H-NMR (300MHz, DMSO-d6): δ11.78(s,1H),9.48(s,1H),8.50(m,3H),7.53(s,1H),7.38(s,1H),7.28(s,1H) ,6.96(d,1H),6.67(s,1H),5.10(t,1H),4.42(d,1H),2.43(s,3H),1.84(m,1H),0.93(m,2H),0.65(m,2H).
[0423] Process 3) 3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzaldehyde
[0424]
[0425] 5.67 g (14.00 mmol) of (3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylphenyl)methanol prepared according to Example 25, process 2) was dissolved in 200 mL of dichloromethane, and then 14.3 g (140.00 mmol) of manganese dioxide was added thereto. The resulting mixture was stirred at room temperature for 18 hours. When the reaction was completed, the resulting mixture was filtered through a filter filled with diatomaceous earth and washed with dichloromethane. The obtained organic layer was concentrated under reduced pressure. The obtained residue was purified using MPLC (ethyl acetate:hexane=1:4 (v / v)), and the obtained solution was concentrated under reduced pressure to obtain 2.1 g of the target compound with a yield of 37%.
[0426] 1 H-NMR (300MHz, DMSO-d6): δ11.81(s,1H),9.90(s,1H),9.78(s,1H),8.50(m,3H),8.15(s,1H) ,7.81(s,1H),7.25(d,2H),6.94(d,2H),2.42(s,3H),1.97(m,1H),1.02(m,2H),0.75(m,2H).
[0427] Process 4) Preparation of (R)-5-chloro-N-(3-cyclopropyl-5-((3,3,5-trimethylpiperazin-1-yl)methyl)phenyl)- 4-(6-Methyl-1H-indol-3-yl)pyrimidin-2-amine
[0428]
[0429] 140 mg (0.35 mmol) of 3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzaldehyde prepared according to process 3) of Example 25 and 140 mg (0.70 mmol) of (R)-2,2,6-trimethylpiperazine hydrochloride were dissolved in 2 mL of 1,2-dichloroethane, and 200 mg (0.75 mmol) of sodium triacetoxyborohydride and 0.3 mL (1.74 mmol) of diisopropylamine were added thereto. The mixture was stirred at room temperature for 3 hours. When the reaction was completed, dichloromethane and a saturated aqueous sodium bicarbonate solution were added dropwise thereto. An organic layer was extracted therefrom, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified using MPLC (dichloromethane:methanol=25:1 (v / v)), and the obtained solution was concentrated under reduced pressure to obtain 140 mg of the target compound with a yield of 78%.
[0430] MS (ESI+, m / z): 515 [M+H] +
[0431] 1 H-NMR (300MHz, DMSO-d6): δ11.77(s,1H),9.47(s,1H),8.48(m,3H),7.57(s,1H),7.35(s,1H),7.28(s,1H),6.94(d,1H),6.64(s,1H) ,3.38(q,2H),2.95(m,1H),2.70(d,1H),2.43(s,3H),1.84(m,1H),1.59(m,2H),1.23(d,1H),1.12(s,3H),0.94(m,2H),0.63(m,2H).
[0432] Example 26: ((2R,6R)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-6-methylpiperazin-2-yl)methanol
[0433]
[0434] 22 mg of the target compound was obtained in a 24% yield in essentially the same manner as process 4) of Example 25, except that 55 mg (0.27 mmol) of ((2R,6R)-6-methylpiperazin-2-yl)methanol hydrochloride was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride.
[0435] MS (ESI+, m / z): 517 [M+H] +
[0436] 1 H-NMR (300MHz, DMSO-d6): δ11.80(s,1H),9.49(s,1H),8.48(m,3H),7.50 (s,1H),7.40(s,1H),7.33(s,1H),6.95(d,1H),6.65(s,1H),4.99(m,1H) ,4.10(m,1H),3.42(s,2H),3.16(d,2H),2.97(m,2H),2.80(m,2H),2.43( s,3H),1.85(m,3H),1.23(m,2H),1.04(d,3H),0.94(m,2H),0.65(m,2H).
[0437] Example 27: (R)-5-chloro-N-(3-cyclopropyl-5-((5-methyl-4,7-diazaspiro[2.5]octan-7-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0438]
[0439] 150 mg of the target compound was obtained in 60% yield in substantially the same manner as process 4) of Example 25, except that 188 mg (1.49 mmol) of (R)-5-methyl-4,7-diazaspiro[2.5]octane hydrochloride was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride.
[0440] 1 H-NMR (300MHz, DMSO-d6): δ11.77(s,1H),9.46(s,1H),8.47(m,3H),7.47(s,1H),7.40(s,1H),7.28(s,1H),6.95(d,1H) ,6.64(s,1H),2.71(d,2H),2.62(d,2H),2.42(s,3H),1.87(m,1H),1.50(q,2H),1.23(q,2H),0.92(m,8H),0.62(m,2H).
[0441] Example 28: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5R)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0442]
[0443] 17 mg of the target compound was obtained in a 9% yield in substantially the same manner as process 4) of Example 25, except that 149 mg (0.80 mmol) of (2R,6R)-2,6-dimethylpiperazine hydrochloride was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride.
[0444] MS (ESI+, m / z): 501 [M+H] +
[0445] 1 H-NMR (300MHz, DMSO-d6): δ11.80(s,1H),9.15(s,1H),8.46(m,3H),7.66(s,1H),7.35(s,1H),7.28(s,1H),6.95 (d,1H),6.63(s,1H),3.51(d,2H),2.43(s,3H),2.25(m,2H),1.85(m,1H),1.23(s,2H),0.91(m,4H),0.62(m,2H).
[0446] Example 29: 5-Chloro-N-(3-cyclopropyl-5-(((3S,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0447]
[0448] 25 mg of the target compound was obtained in a 15% yield in substantially the same manner as process 4) of Example 25, except that 75 mg (0.66 mmol) of (2S,6S)-2,6-dimethylpiperazine hydrochloride was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride.
[0449] MS (ESI+, m / z): 501 [M+H] +
[0450] 1 H-NMR (300MHz, DMSO-d6): δ11.76(s,1H),9.46(s,1H),8.46(m,3H),7.55(s,1H),7.35(s,1H),7.27(s,1H),6.94(d,1H) ,6.63(s,1H),3.59(t,2H),3.05(m,2H),2.32(d,2H),1.89(m,2H),1.75(m,1H),1.01(d,6H),0.91(m,2H),0.62(m,2H).
[0451] Example 30: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,4,5-trimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
[0452]
[0453] 70 mg of the target compound was obtained in 79% yield in substantially the same manner as process 4) of Example 25, except that 168 mg (0.70 mmol) of (2R,6S)-1,2,6-trimethylpiperazine trifluoroacetate was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride.
[0454] MS (ESI+, m / z): 515 [M+H] +
[0455] 1 H-NMR (300MHz, DMSO-d6): δ11.76(s,1H),9.46(s,1H),8.46(m,3H),7.48(s,1H),7.40(s,1H),7.28(s,1H),6.95(d,1H) ,6.64(s,1H),4.34(m,1H),3.47(m,1H),2.63(m,2H),2.43(s,3H),2.15(m,2H),1.82(m,2H),1.08(m,8H),0.62(m,2H).
[0456] Example 31: (2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-ol
[0457]
[0458] 60 mg of the target compound was obtained in 94% yield in essentially the same manner as process 4) of Example 25, except that 62 mg (0.37 mmol) of (2R,6S)-2,6-dimethylpiperazin-1-ol hydrochloride was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride.
[0459] MS (ESI+, m / z): 517 [M+H] +
[0460] 1H-NMR (300MHz, DMSO-d6): δ11.77(s,1H),9.48(s,1H),8.47(m,3H),7.67(s,1H),7.47(s,1H),7.41(s,1H),7.28(s,1H) ,6.95(d,1H),6.63(s,1H),3.31(s,2H),2.69(d,2H),2.43(s,3H),1.81(m,3H),1.05(t,2H),0.95(m,8H),0.62(m,2H).
[0461] Example 32: (2R,6S)-4-(3-cyclopropyl-5-((4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)benzyl)-2,6-dimethylpiperazin-1-ol
[0462]
[0463] 1.5 mg of the target compound was obtained in a 51% yield in essentially the same manner as in Example 25, except that in process 4) of Example 25, 2.5 g (12.16 mmol) of (2R,6S)-2,6-dimethylpiperazin-1-ol hydrochloride was used instead of (R)-2,2,6-trimethylpiperazine hydrochloride, and 2.24 g (6.08 mmol) of 3-cyclopropyl-5-((4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)benzaldehyde was used instead of 3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzaldehyde.
[0464] MS (ESI + ,m / z):483[M+H] +
[0465] 1 H-NMR (300MHz, DMSO-d6): δ11.63(bs,1H),9.23(s,1H),8.45(d,1H),8.29(m,1H),8.20(s,1H),7.66(s,1H),7.51(d,2H ),7.22(m,2H),6.96(d,1H),6.58(s,1H),2.73(m,2H),2.55(m,4H),1.88(m,1H),1.82(m,2H),0.96(m,8H),0.64(m,2H).
[0466] Experimental example
[0467] The kinase inhibitory activity and cell growth inhibitory activity of the aforementioned compounds prepared in the Examples were evaluated. The results are as follows.
[0468] Experimental Example 1: Evaluation of kinase inhibitory activity
[0469] The inhibitory activities of some of the above compounds against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR) and SYK kinases were measured.
[0470] The inhibitory activity of the compound against mutant proteins such as FLT3 WT and ITD was evaluated based on the LanthaScreen technology developed by Thermo Fisher Scientific Inc. This test is based on The binding of a 647-labeled, ATP-competitive kinase inhibitor (kinase tracer-236) to the kinase and the signal of fluorescence resonance energy transfer (FRET) is measured in the presence of a europium-conjugated antibody. The experiment was performed in a 384-well plate under conditions including 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA and 1% DMSO. The background signal was measured in the absence of a protein such as FLT3 or FLT3-ITD, and the non-inhibitory signal was measured by adding only solvent (1% DMSO). The evaluated compound was used at a set concentration (e.g., 50 nM to 0.05 nM, 1:10 dilution) to calculate the kinase inhibitory activity IC of the evaluated compound. 50 The results are shown in Table 2 below.
[0471] [Table 2]
[0472] Kinase inhibitory activity of pyrimidine compounds against FLT3 ITD and WT
[0473]
[0474]
[0475] As shown in Table 2, the compounds of the present disclosure showed excellent kinase inhibitory activity against FLT3 ITD and WT.
[0476] The SYK inhibitory activity of the compound is evaluated based on the z-LYTE technology developed by Thermo Fisher Scientific Inc. According to this evaluation method, the fluorescence signal of the FRET-peptide is measured, wherein the fluorescence of the FRET-peptide phosphorylated by the binding of the compound to the target, and the fluorescence of the non-phosphorylated peptide is measured to identify the activity in terms of kinase. This experiment was carried out on a 384-well plate under conditions including 50mM HEPES pH 7.5, 0.01% BRIJ-35, 10mM MgCl2, 1mM EGTA and 1% DMSO. The background signal is measured in the absence of protein; the non-inhibitory signal is measured only when the solvent (1% DMSO) is added; and the compound evaluated is used at a concentration of 100nM, and the SYK inhibitory activity of the compound is calculated as a percentage (%). The z-lyte kinase assay kit (Life Technologies, PV 3190) is used for VEGFR, and the test is performed by LifeTechnologies Inc. Table 3 shows the percentage (%) of the inhibitory activity of the compound to the corresponding kinase when the compound concentration is 100nM.
[0477] [Table 3]
[0478] Inhibitory activity of pyrimidine compounds on VEGFR2 and SYK kinases (percentage, %)
[0479] Compound VEGFR2 (% inhibition) SYK (% inhibition) Example 1 95 73 Example 5 71 78 Example 8 100 95
[0480] As shown in Table 3, the compounds according to the present disclosure have excellent VEGFR2 and SYK kinase inhibitory activities.
[0481] Experimental Example 2: Evaluation of cell growth inhibitory activity
[0482] Human acute myeloid leukemia (ALL) cell line MOLM-13 (DSMZ No. ACC 554) was cultured in RPMI1640 medium supplemented with 20% heat-deactivated FBS at 37°C. 4 The test compound was prepared in an amount of 1 μM cells / 100 μL and then inoculated on a 96-well plate. The test compound was serially diluted with RPMI1640 medium at a ratio of 1:10 to a concentration ranging from 1 μM to 0.01 nM. Subsequently, the culture was performed thereon for three days. For the human acute myeloid leukemia cell line MV-4-11 cell line ( CRL-9591 TM ), and the cells were cultured in IMDM medium supplemented with 10% FBS at 37°C. The cultured cell line was cultured at 2.0×10 4The cells were prepared in an amount of 10 cells / 100 μL and then seeded on a 96-well plate. The IMDM medium was treated with a serial dilution of the three test compounds at a ratio of 1 / 10 in the range of 1 μM to 0.01 nM. Subsequently, cultivation was performed on it for three days. The MTS assay was performed to measure cell viability, and the growth inhibition (GI) of the cell lines was calculated using GraphPad Prism software. 50 The results of each cell line are shown in Table 4 below.
[0483] [Table 4]
[0484] Cytostatic Activity of Pyrimidine Compounds
[0485]
[0486]
[0487] As shown in Table 4, the compounds of the present disclosure were found to have excellent growth inhibitory activity on acute myeloid leukemia (ALL) cell lines.
[0488] Experimental Example 3: Evaluation of Pharmacokinetic Curves
[0489] After the test substance was formulated with the selected solvent, it was orally (po) and intravenously (iv) injected once each, and a certain amount of blood was taken at a predetermined time, and plasma was separated from the blood, and concentration analysis was performed on it by LC-MS / MS. AUC (drug concentration and area under the curve) was calculated according to the linear-log trapezoidal summation formula by non-compartmental analysis using the WinNonlin program through the plasma concentration over time curve. The bioavailability (BA) was calculated by applying the calculated AUC value to the following formula. BA (%) = (AUC po / AUC iv) × (dose iv / dose po) × 100
[0490] [Table 5]
[0491] Bioavailability and area under the curve of pyrimidine compounds
[0492]
[0493] [Table 6]
[0494] Bioavailability and area under the curve of pyrimidine compounds
[0495]
[0496] As shown in Table 5 and Table 6, it is shown that the compounds according to the embodiments of the present disclosure are more suitable for oral administration than the control compounds having similar chemical structures to the compounds in terms of absorption characteristics such as bioavailability and area under the curve.
[0497] Experimental Example 4: Microsome Stability Measurement Method
[0498] To confirm the reactivity of the test substance with the intrahepatic CYP450 enzyme, 5 μM of the test substance and 1 mg / ml of human liver microsomes were incubated at 37°C for 1 hour in the presence of an NADPH regeneration system. After 1 hour, acetonitrile was added to terminate the reaction, and the supernatant obtained by centrifugation was analyzed by HPLC. The remaining amount % was calculated using the following equation, using the value of the 1-hour reaction sample relative to the value of the 0-minute sample, and the resulting peak value was used as the analysis result. (Peak value of the sample at 1 hour of reaction / Peak value of the sample at 0 minutes) × 100 = Residual amount %
[0499] [Table 7]
[0500] Microsomal stability of pyrimidine compounds
[0501]
[0502] As shown in Table 7, the compounds according to embodiments of the present disclosure have improved microsomal stability compared to control compounds having similar chemical structures thereto.
[0503] As can be seen from the example data, compounds according to embodiments of the present disclosure were found to have better pharmacokinetic properties than control compounds having similar substituents and comparable levels of steric hindrance thereto.
[0504] The compound according to one aspect of the present disclosure is excellent in FLT3 inhibitory activity, and thus can be effectively used for preventing or treating cell proliferative diseases such as cancer, for example, leukemia, etc., caused by abnormal FLT3 activity.
[0505] In summary, the present invention includes but is not limited to the following items:
[0506] 1. A compound selected from the group consisting of compounds represented by formula 1, and stereoisomers, tautomers, solvates or pharmaceutically acceptable salts thereof,
[0507] [Formula 1]
[0508]
[0509] Among them, in formula 1,
[0510] R 1 is hydrogen, halogen, hydroxy, C1-C4 alkoxy or -NR a R b ,
[0511] Among them, R a and R bEach is independently hydrogen or C1-C4 alkyl;
[0512] R 2 is hydrogen, halogen, cyano, nitro, amino, carboxamide, formyl, halogenated C1-C4 alkyl or C1-C4 alkyl;
[0513] R 3 is hydrogen, halogen, hydroxy, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl;
[0514] R 4 are independently hydrogen, halogen, hydroxy, cyano, nitro, amino, S(═O) l -R c , halogenated C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -NR d R e 、-CO2R e , or -CO-NR d R e ,
[0515] Wherein, Rc is C1-C4 alkyl or -NR d R e ,
[0516] R d and R e are each independently hydrogen or C1-C4 alkyl,
[0517] I is an integer from 0 to 2, and
[0518] k is an integer from 0 to 4;
[0519] R 5 and R 6 Each is independently hydrogen, halogen, hydroxy, nitro, amino, C1-C4 alkoxy or C1-C4 alkyl;
[0520] R 7 is hydroxyC1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C7 cycloalkyl or C3-C9 heterocycloalkyl,
[0521] wherein the C3-C7 cycloalkyl group or the C3-C9 heterocycloalkyl group is unsubstituted or substituted by halogen, C1-C4 alkyl group or halogenated C1-C4 alkyl group; and
[0522] X is H or OH;
[0523] Wherein, when X is OH, the compound represented by Formula 1 includes a tautomeric structure represented by Formula 2,
[0524] [Formula 2]
[0525]
[0526] R in Formula 2 3 , R 4 and k are the same as described with respect to Formula 1;
[0527] Y is -(CH2) m -、-(CH2) m -O-(CH2) n -、-(CH2) m -CO-(CH2) n -、-(CH2) m -NR 8 -(CH2) n -or-(CH2) m -SO2-(CH2) n -,
[0528] Among them, R 8 is hydrogen or C1-C4 alkyl,
[0529] m and n are each independently an integer from 0 to 2; and
[0530] Z is represented by formula 3;
[0531] [Formula 3]
[0532]
[0533] Among them, in formula 3,
[0534] C3-C 10 Cycloalkyl or C2-C 11 Heterocycloalkyl;
[0535] R 9 is halogen, hydroxyl, cyano, nitro, amino, thiol, formyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, straight-chain or branched hydroxy C1-C4 alkyl, straight-chain or branched C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl, C2-C9 heterocycloalkyl, hydroxy C2-C9 heterocycloalkyl, straight-chain or branched hydroxy C1-C4 alkylcarbonyl, -NR 10 R11, -COR 12 、-COOR 12 or-SO2R 13 ,
[0536] q is an integer from 0 to 5,
[0537] Among them, when When is piperazine or piperidine, q is not 0, and
[0538] Among them, two or more R 9 Connect or fused to form a 7- to 12-membered bicycloalkyl, heterobicycloalkyl, spirocycloalkyl or spiroheterocycloalkyl;
[0539] R 10 and R 11 Each is independently hydrogen, hydroxy C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl;
[0540] R 12 is hydrogen, hydroxy, hydroxy C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl or C2-C9 heterocycloalkyl;
[0541] R 13 is hydroxyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl, C2-C9 heterocycloalkyl, aryl or -NR f R g ,and
[0542] R f and R g Each is independently hydrogen or C1-C4 alkyl.
[0543] 2. The compound according to item 1, wherein R 3 It is hydrogen, hydroxy or C1-C4 alkyl.
[0544] 3. The compound according to item 1, wherein R 4 It is hydrogen, halogen, hydroxy, cyano, nitro, amino, halogenated C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl.
[0545] 4. The compound according to item 1, wherein R 5 and R 6 Each is independently hydrogen, halogen, hydroxy, cyano or C1-C4 alkyl.
[0546] 5. The compound according to item 1, wherein R 7 It is a C3-C7 cycloalkyl group.
[0547] 6. The compound according to item 5, wherein R 7 It is cyclopropyl.
[0548] 7. The compound according to item 1, wherein Y is -(CH2) m -, wherein m is an integer selected from 1 and 2.
[0549] 8. The compound according to item 1, wherein R 12 is hydrogen, hydroxy C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C 2-4 Alkynyl; and R 13 It is hydroxy, halogenated C1-C4 alkyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl.
[0550] 9. The compound according to item 1, wherein Z is any one selected from Formula 11 to Formula 13:
[0551] [Formula 11]
[0552]
[0553] [Formula 12]
[0554]
[0555] [Formula 13]
[0556]
[0557] Wherein, in Formulas 11 to 13,
[0558] V and W are each independently N or CH, provided that V and W are each not CH at the same time,
[0559] R 14 is hydrogen, halogen, straight chain or branched C1-C4 alkyl, straight chain or branched hydroxy C1-C4 alkyl, hydroxy, -NR 16 R 17 , a straight or branched hydroxy C1-C4 alkylcarbonyl, a C2-C9 heterocycloalkyl, a hydroxy C2-C9 heterocycloalkyl, a straight or branched halogenated C1-C4 alkyl, or a straight or branched C1-C4 alkoxy,
[0560] R 15 Each is independently a linear or branched C1-C4 alkyl group, a linear or branched hydroxy C1-C4 alkyl group, or a halogen,
[0561] R 14 and R 15 connected to each other, or R 14 or R 15is fused with a cyclic compound represented by one of Formulae 11 to 13 to form a 7- to 12-membered bicycloalkyl, heterobicycloalkyl, spirocycloalkyl or spiroheterocycloalkyl,
[0562] R 16 and R 17 Each is independently hydrogen, a linear or branched C1-C4 alkyl group, or a linear or branched hydroxy C1-C4 alkyl group,
[0563] p is an integer from 0 to 4; and
[0564] When R 14 When R is hydrogen, s and t are each independently an integer from 0 to 5, and when R 14 When it is not hydrogen, s and t are each independently an integer from 0 to 4.
[0565] 10. A compound selected from the group consisting of compounds represented by formula 14, and stereoisomers, tautomers, solvates or pharmaceutically acceptable salts thereof,
[0566] [Formula 14]
[0567]
[0568] Among them, in formula 14,
[0569] E a is hydrogen, hydroxy or C1-C4 alkoxy;
[0570] E b is hydrogen, halogen, C1-C4 alkyl or C1-C4 fluoroalkyl;
[0571] E c and E d are each independently hydrogen or hydroxy;
[0572] X' is hydrogen or hydroxyl;
[0573] k is an integer from 0 to 4;
[0574] Q is each independently hydroxy, halogen, C1-C4 alkyl, hydroxyC1-C4 alkyl or C1-C4 alkoxy; and
[0575] Z' is a monovalent functional group represented by formula 15;
[0576] [Formula 15]
[0577]
[0578] Wherein, in Formula 15, n is an integer from 1 to 8;
[0579] A is each independently a functional group selected from hydroxy, C1-C4 alkyl and hydroxyC1-C4 alkyl, wherein when n is two or more, two of the two or more A are connected to each other to form an alkylene bridge to form a 7- to 12-membered bridged heterobicycloalkyl ring Z', or two A are spirally connected to form a 7- to 12-membered spiroheterocycloalkyl ring; and
[0580] L is hydrogen, C1-C4 alkyl, hydroxy or hydroxyC1-C4 alkyl.
[0581] 11. The compound according to item 10, wherein E b is halogen, n is 2, and A is methyl.
[0582] 12. The compound according to item 10, wherein Z' is 3,5-dimethylpiperazin-1-yl.
[0583] 13. The compound according to item 10, wherein E b is chlorine or fluorine.
[0584] 14. The compound according to item 1, wherein the compound of formula 1 is selected from the following compounds:
[0585] 1) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-amine;
[0586] 2) 5-chloro-4-(6-chloro-1H-indol-3-yl)-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-amine;
[0587] 3) 2-((2R,6S)-4-(3-((5-chloro-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol;
[0588] 4) 2-((2R,6S)-4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol;
[0589] 5) 2-((2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol;
[0590] 6) (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine;
[0591] 7) (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0592] 8) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0593] 9) 5-chloro-N-(3-cyclopropyl-5-(((3S,5R)-3-ethyl-5-methylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0594] 10) 5-chloro-N-(3-cyclopropyl-5-((3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0595] 11) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0596] 12) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-fluoro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0597] 13) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)-5-methylpyrimidin-2-amine;
[0598] 14) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-methyl-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0599] 15) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-amine;
[0600] 16)(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-1H-indol-6-yl)methanol;
[0601] 17) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(5-methoxy-6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0602] 18) 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-6-methyl-1H-indol-5-ol;
[0603] 19) 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-6-methylindolin-2-one;
[0604] 20) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-methoxy-6-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0605] 21) 5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)-6-(6-methyl-1H-indol-3-yl)pyrimidin-4-ol;
[0606] 22) 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-6-methyl-1H-indol-7-ol;
[0607] 23) 2-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-4-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol;
[0608] 24) 4-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-2-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol;
[0609] 25) (R)-5-chloro-N-(3-cyclopropyl-5-((3,3,5-trimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0610] 26)((2R,6R)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-6-methylpiperazin-2-yl)methanol;
[0611] 27) (R)-5-chloro-N-(3-cyclopropyl-5-((5-methyl-4,7-diazaspiro[2.5]octan-7-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0612] 28) 5-chloro-N-(3-cyclopropyl-5-(((3R,5R)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0613] 29) 5-chloro-N-(3-cyclopropyl-5-(((3S,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0614] 30) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,4,5-trimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine;
[0615] 31)(2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-ol; and
[0616] 32)(2R,6S)-4-(3-cyclopropyl-5-((4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)benzyl)-2,6-dimethylpiperazin-1-ol.
[0617] 15. A pharmaceutical composition for preventing or treating cancer, comprising the compound according to any one of items 1 to 14 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0618] 16. The pharmaceutical composition according to item 15, wherein the cancer comprises leukemia.
[0619] 17. The pharmaceutical composition according to item 16, wherein the leukemia comprises acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia.
[0620] 18. A pharmaceutical composition for inhibiting FLT3 kinase activity, the pharmaceutical composition comprising: a compound according to any one of items 1 to 14 or a pharmaceutically acceptable salt thereof; and a pharmacologically acceptable excipient.
[0621] Although the present disclosure has been particularly shown and described by reference to its example embodiments, it will be understood by those skilled in the art that various changes in form and details may be made without departing from the spirit and scope of the present disclosure as defined in the appended claims. The example embodiments should be regarded as descriptive only and not for the purpose of limitation. Therefore, the scope of the present disclosure is not defined by the detailed description of the present disclosure, but by the appended claims, and all differences within the scope will be interpreted as included in the present disclosure.
Claims
1. Use of a pharmaceutical composition in the preparation of a drug for preventing or treating cancer, the pharmaceutical composition comprising a compound selected from the following: 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-amine (1); 5-Chloro-4-(6-chloro-1H-indol-3-yl)-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-amine (2); 2-((2R,6S)-4-(3-((5-chloro-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol (3); 2-((2R,6S)-4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol (4); 2-((2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol (5); (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine (6); 5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine (8); 5-Chloro-N-(3-cyclopropyl-5-((3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine (10); N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-fluoro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine (12); N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)-5-methylpyrimidin-2-amine (13); (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-1H-indol-6-yl)methanol (16); 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-6-methyl-1H-indol-5-ol (18); 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amine)pyrimidin-4-yl)-6-methyl-1H-indol-7-ol (22); (R)-5-chloro-N-(3-cyclopropyl-5-((3,3,5-trimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine (25); ((2R,6R)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-6-methylpiperazin-2-yl)methanol (26); 5-chloro-N-(3-cyclopropyl-5-(((3R,5R)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine (28); and (2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amine)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-ol (31); or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmacologically acceptable excipient, and wherein the cancer is associated with a FLT3-ITD mutation.
2. The use according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof.
3. The use according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof.
4. The use according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof.
5. The use according to any one of claims 1-4, wherein the FLT3 mutation is at least at the aspartic acid 835 residue of FLT3.
6. The use according to claim 5, wherein the FLT3 mutation is D835V or D835Y.
7. The use according to any one of claims 1-4, wherein the cancer comprises leukemia.
8. The use according to claim 7, wherein the leukemia comprises acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia.
